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ABSTRACT
We previously demonstrated that human papillary thyroid carcinomas (PTCs)
display ??M????C???????? infiltrate correlate? with extrathyroidal extension.
MCs (MC) are mainly found at the invasive front of human PTCs, where they
may facilitate tumor cell migration and extracellular matrix degradation. The
increased  motility  and  invasiveness  of  tumor  cells  are  reminiscent  of  the
epithelial to mesenchymal transition (EMT). However, the MC-derived factors
that mediate this activity and the mechanisms with which they enhance thyroid
carcinoma (TC) invasive ability remain unidentified. Here, we report that MC-
derived  conditioned  media  (MC  CM)  induce  the  epithelial-to-mesenchimal
transition  (EMT)  and  the  gain  of  stemness  features  of  TC cells.  MC CM-
treated  thyroid  cancer  (TC)  cells  down-regulate  E-cadherin  expression,  an
epithelial  protein,  while  up-regulating  EMT  transcription  factors  (SNAIL,
SLUG,  ZEB1)  and  mesenchimal  markers  (vimentin).  Here  we  identify
interleukin 8 (CXCL8/IL-8) as the main mediator produced by MCs capable of
inducing both EMT and stemness in TC cells. TC cells infact express both the
IL-8 receptors, CXCR1 and CXCR2. Immune depletion of IL-8 from MC CM
completely  abolishes  EMT  and  stemness.  Treatment  of  TC  cells  with
recombinant IL-8 induces these features, and blocking molecules targeting the
IL-8/CXCR1/CXCR2 axis revert them.  850-5C cells, derived from a human
anaplastic thyroid carcinoma (ATC),  enforced to express IL-8, undergo EMT,
display increased stemness, and are more efficient in tumor formation when
xenografted  in  immunodeficient  mice  with  respect  to  parental  cells.  The
transcription  factor  SLUG may  be  a  critical  mediator  of  IL-8-mediated
biological effects in TC cells; in fact, IL-8 treatment causes persistent SLUG
upregulation,  and  IL-8  expressing  850-5C  cells  constitutively  express  high
levels of SLUG. We generated TPC-1 cells, derived from a human PTC, with
enforced  expression  of  SLUG.  These  cells  underwent  EMT and  exhibited
stemness features, including the capability to form spheres in low-adherence
condition. By analysing a panel  (n=30) of  human TC surgical  samples, we
observed that  the  expression  of  the  stemness  marker  OCT4 is significantly
associated with tumor size and with MC density. Furthermore,  we observed
that IL-8 expression correlates with the presence of lymph-node metastases and
with SLUG expression.
The failure in the eradication of CSCs is likely one of the factors that limits the
efficacy of current therapeutic approaches against cancer. Thus, novel CSCs-
targeted treatments are needed. In this regard, our study  provides the evidence
that targeting MC-derived IL-8 may be employed to directly target CSCs in
advanced thyroid cancer.
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1. BACKGROUND
1.1 Thyroid Cancer
The  thyroid  gland  develops  in  the  embryo  as  a  tubular  evagination  of  the
pharyngeal endoderm at the basis of the tongue. It is located in the neck, beside
the trachea. The thyroid gland is composed by two distinct hormone-producing
cell types: follicular cells and parafollicular  C cells. Follicular cells comprise
most  of  the  epithelium  and  are  responsible  for  iodine  uptake  and  thyroid
hormone synthesis.  C  cells are scattered intrafollicular or parafollicular cells
and  are  dedicated  to  the  production  of  the  calcium-regulating  hormone
calcitonin. Extimates of 2012 reveal thyroid cancer (TC) as the fifth expected
malignancy in American women and is the most common malignancy of the
endocrine system (Peter M Sadow and William C. Faquin 2012 ). More than
95% of TC are derived from follicular cells while a minority of tumors (3%),
referred to as medullary thyroid carcinoma, are of C-cell origin.
TC affects women more often than men and usually occurs in people between
the  ages  of  25  and  65  years.  The  incidence  of  this  malignancy  has  been
increasing over the last decade (Pellegritti G et al. 2013).
Patients with a history of radiation administered in infancy and childhood for
benign conditions of the head and neck, such as enlarged thymus, acne,  or
tonsillar or adenoidal enlargement, have an increased risk of cancer as well as
other abnormalities of the thyroid gland (Ciampi et al. 2005). Other risk factors
for the development of TC include a history of goiter, family history of thyroid
disease, female gender. 
Thyroid  carcinomas  are  broadly  divided  into  well-differentiated,  poorly
differentiated  and  undifferentiated  types  on  the  basis  of  histological  and
clinical parameters. Differentiated tumors (papillary or follicular)  are highly
treatable  and  usually  curable.  Poorly  differentiated  tumors  (medullary  and
anaplastic) are much less common, are aggressive, metastasize early, and have
a much poorer prognosis (DeLellis et al. 2004). Papillary thyroid carcinoma
(PTC) is the most common thyroid malignancy; it accounts for 75 to 80% of all
thyroid cancers, showing an incidence peak at 40-50 years. A well established
cause of PTC is  the exposure to  ionizing radiations,  especially in  the neck
region; in fact, about 2-4% of the patients irradiated to treat deseases such as
acne or enlarged thymus, develop a differentiated thyroid carcinoma after about
20-30 years. Accordingly, the frequency of PTC is dramatically increased in
the children exposed to the massive release of radionuclides that followed the
explosion of the nuclear reactor in Chernobyl in 1986 (DeLellis, 2006). PTC
shows  typically  multicentricity  and  a  tendency  to  spread  into  lymphatic
vessels;  regional  node metastases  at  presentation  are  found in  a  significant
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proportion of cases. There are several PTC variants including solid-follicular,
follicular,  tall-cell,  hurthle  cell  variants  (Ostrowski  et  al.  1996).  Follicular
thyroid carcinoma (FTC) is less frequent than PTC and represents about 10-
30% of thyroid cancers; it  is particularly linked to dietary iodine deficiency
(Williams et al.1997) and both iodine deficiency and genetic influences could
account for its link with a history of nodular goiter (Ron E et al. 1987). FTC
shows  variable  morphology  ranging  from  well-formed  colloid-containing
follicles, to solid or trabecular growth pattern. Therapy for both PTC and FTC
consists in surgery followed by metabolic treatment with I131. Prognosis is very
good with a survival rate at 10 years ranging from 90 to 98%.
Anaplastic  thyroid  carcinoma (ATC) is  the most  aggressive type  of  thyroid
cancer. ATC cells are extremely abnormal and spread rapidly to other parts of
the body. ATC make up only about 1% of all  thyroid cancers and typically
spreads beyond the thyroid by direct local extension.  Metastasis to regional
nodes are also common but their presence is often masked by the presence of
extensive  soft  tissue  invasion.  No effective  therapy is  known for  ATC and
prognosis is very unfavorable with a mean survival time of less than one year
(Giuffrida et al.  2000). Poorly differentiated thyroid carcinoma (PDTC) is a
recent diagnosis for rare aggressive thyroid tumors that represent the bridge
between  more  well  differentiated  malignancies  of  thyrocytes  and  the
undifferentiated thyroid carcinomas (Siironen P et al. 2010).
PDTCs demonstrate solid, trabecular, and insular components, the absence of
conventional nuclear patterns of papillary carcinoma, and the presence of at
least  one  of  the  following  features:  convoluted  nuclei,  mitotic  activity,  or
necrosis  (Katsuhiro Tanaka et  al.  2011). Many reports  have demonstrated a
poorer  survival  among  PDTC  patients  than  among  those  with  well-
differentiated carcinoma (WDTC)(M. Decaussin et al. 2002, M. Volante et al.
2004, T. Nishida et al. 1999).
Despite favorable prognosis of WDTC, ~5% of them progress to radioactive
iodine-refractory  (RAIR),  which  commonly  leads  to  death  within  5  years
(Pacini  F  et  al.  2012).  I131 RAIR  can  be  defined  as  an  inability  of
malignant/metastatic tissue to take up I131 from the start of treatment or loss of
ability to take up I131 after  previous evidence of uptake.  It  is detected by a
combination of imaging modalities, including an I131 whole body scan showing
at least one lesion that does not take up I131, or clinical evidence that I131 is no
longer providing benefit to the patient (David G. Pfister and James A. Fagin
2008).  Standard  cytotoxic  chemoterapy  has  limited  efficacy,  making
introduction in clinical trials of novel targeted therapies (Pacini F et al. 2012 ),
Medullary thyroid carcinoma (MTC) develops from neuroendocrine C cells of
the thyroid, producing calcitonin (CT). About 5 to 7% of all TC are MTC that
can be sporadic or familial as part of the Multiple Endocrine Neoplasia type 2
syndromes.  MEN2 syndromes are inherited cancer disorders including three
types: MEN2A, characterized by MTC, pheochromocytoma and parathyroid
adenoma; MEN2B characterized by MTC, pheochromocytoma and additional
tumors such as neuromas and ganglioneuromas of the gut; Familial Medullary
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Thyroid Carcinoma or FMTC whose only feature is MTC. MEN2 is inherited
as a highly penetrant mendelian tract and this genetic transmission is due to
gain-of-function  mutations  of  the  RET gene.  MTC tends  to  metastasize  to
lymph-nodes and distant organs, and its treatment consists in surgical removal
of the lesion. MTC are fairly resistant to most chemotherapeutic agents (Core
et al.2003). Fig.1
Figure 1: Features of thyroid tumors (Modified from Williams 2002).
1.2 Molecular genetics of thyroid tumors
PTC
Several  studies  on  thyroid  tumors  have  allowed  the  identification  of  many
genetic alterations. In particular, four genetic lesions, at the somatic level, are
16
associated with PTC. They include chromosomal aberrations targeting the RET
or  TRKA tyrosine  kinase  receptors  and  point  mutations  in  RAS or  BRAF
genes. RET(Rearranged during Transfection)  and  NTRK1 are involved in the
pathogenesis of papillary thyroid carcinoma (PTC), with RET alterations being
more  common  than  NTRK1 rearrangements  (Santoro  M  et  al.  1995,
Bongarzone I et al.  1999).  Both genes code for neurotrophic growth factor
receptors with tyrosine kinase activity. Approximately 20–40% of PTCs exhibit
rearrangements of one of these genes with other coding sequences,  forming
chimeric oncogenes, including RET/PTC. In RET/PTC rearrangements, fusion
with protein partners, possessing protein-protein interaction domains, provides
RET/PTC proteins the ability to constitutively dimerize, thereby resulting in
ligand-independent activation of c-Ret tyrosine kinase activity (Santoro et al.
1995). RET/PTC1, the CCDC6-RET fusion, and RET/PTC3, the NCOA4-RET
fusion,  are  the  most  prevalent  variants.  RET/PTC3  is  frequently  found  in
radiation-associated-PTC occurred after the Chernobyl accident.
The RAS family of proto-oncogenes includes KRAS, and HRAS and NRAS, all
of  which  are  membrane-bound  GTP/GDP-binding  (G)  molecules.  These
proteins transfer signals from activated tyrosine receptors to pathways that lead
to  the  synthesis  of  key  proteins  involved  in  cell  growth,  proliferation  and
survival.  Although  Ras  mutations  have been observed in  10–15% of PTCs,
they are  more commonly associated  with FTC and the  follicular  variant  of
papillary cancer (Zhu Z et al. 2003). ARaf, BRaf and CRaf are isoforms of the
mammalian  Raf  serine–threonine  kinase  that  participate  in  the
RAF/MEK/MAPK pathway. BRAF mutations, observed in nearly 40% of PTCs
, have been associated with a more aggressive course of disease (Elisei R et al.
2008).  A Glutamine  for  Valine  substitution  at  residue  600  (V600E)  in  the
activation  segment  of  the kinase  accounts  for  more than  90% mutations  of
BRAF in PTC (Kimura et al. 2003; Cohen et al. 2003; Soares et al. 2003). This
mutation enhances BRAF activity through disruption of the autoinhibited state
of the kinase. In human PTC, the genetic alterations of RET/PTC, RAS and
BRAF are mutually exclusive, suggesting the existence of a common signaling
cascade; moreover, mutations at more than one of these sites are unlikely to
provide an additional biological advantage (Kimura et al. 2003, Cohen et al.
2003, Soares et al. 2003).
Among the other genetic anomalies identified in patients with PTC are single-
nucleotide polymorphisms in genes that regulate transcription, upregulation of
microRNAs that modify gene expression and increased methylation of tumor
suppressor  genes  (Hu  S  et  al.  2006).  In  addition,  familial  PTC  has  been
associated with abnormalities in the short arm of chromosome 19 and the long
arms of chromosomes 1,  2 and 8 (Canzian F et  al.  1998, McKay JD et al.
2001), as well as with short telomeres in the germline (Capezzone M et al.
2011).
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FTC
Follicular thyroid carcinoma (FTC) is also a WDTC developing from thyroid
cells. In this carcinoma the presence of K-, H-, and NRAS mutations is quite
common. More recently, it has been shown that a quite high proportion of FTC
carries a translocation involving the  PAX8 promotor gene on the long arm of
chromosome 2 and the PPAR-γ gene on the short arm of chromosome 3 [t(2;3)
(q13;p25)], resulting in the fusion of their DNA-binding domains. PAX8 is a
critical  regulator  of  the  development  and  differentiation  of  follicular
epithelium,  whereas  PPAR-γ is  a  nuclear  hormone  receptor,  normally  not
expressed at high concentrations in thyroid, which is involved in carbohydrate
and lipid metabolism and inflammation (Kroll et al. 2000). 
PDTC and ATC
PDTC is characterized by mutations in  BRAF,  N,  K,  and  HRAS,  as  well  as
translocation of RET/ PTC1, RET/PTC3. 
Point mutations in the  RAS oncogene and in the tumor suppressor p53 have
been described in ATC (Garcia-Rostan et al. 2005, Donghi et al. 1993, Fagin
1993). It is well known that p53 safeguards the cell cycle, the DNA repair and
the apoptotic processes; Garcia-Rostan and colleagues found somatic mutations
within the PI3K catalytic subunit in 23% of analyzed ATC as well as activating
point mutations of β-catenin (Garcia-Rostan et al. 1999). Mutations of BRAF
gene have been detected in anaplastic carcinomas, suggesting that some ATC
may  arise  from  a  preexisting  WDTC,  while  others  may  arise  de  novo
(Nikiforova MN et al. 2003).
MTC
MTC can be sporadic or it could be one of the lesions that characterize the
autosomal dominant MEN 2 syndromes (MEN2A, MEN2B and FMTC). MEN
2 syndromes are caused by germline point mutations that convert  RET into a
dominant  oncogene.  MEN2  patients  are  invariably  affected  by  Medullary
Thyroid  Carcinoma  (MTC),  a  malignant  tumour  arising  from  calcitonin-
secerning C cells of the thyroid. Additional features can be present in MEN2A
(pheochromocytoma  and  parathyroid  adenoma)  and  MEN2B
(pheochromocytoma, mucosal neuroma and ganglioneuroma of the intestine)
(Brandi et al.  2001). In more than 80% of cases, MEN2B is caused by the
Met918Thr substitution in the kinase domain of the receptor. In MEN2A and
most  FMTC  patients,  mutations  affect  one  cysteine  of  the  extracellular
cysteine-rich domain of RET (609, 611, 618, 620, 630, 634) that can change to
different residues. A significant genotype-phenotype correlation is observed. In
particular,  about  90% of  MEN2A patients  have  Cys634  mutation,  and  this
mutation  is  highly  predictive  of  the  presence  of  pheochromocytoma  and
parathyroid hyperplasia. (Santoro et al. 1995; Carlomagno et al. 1997). RET
activation by mutations targeting the intracellular domain is less understood
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(Santoro  et  al.  1995,  Iwashita  et  al.  1999)  but  it  can  be  envisaged  that  a
modification  of  the  structure  of  the  kinase  may  switch  on  its  enzymatic
function. Mutations  in  HRAS and  KRAS genes  were  recently  found  in  a
significant  proportion  of  non-RET-mutated  MTC,  suggesting  that  RAS
mutations  could  represent  alternative  genetic  events  in  sporadic  MTC
tumorigenesis.  This  observation  could  be  of  value  for  defining  therapeutic
strategies in non-RET-mutated tumors (A. Boichard et al. 2012).
1.3 Inflammation and thyroid cancer
The relationship between cancer and inflammation has been observed first in
1863  when  Rudolf  Virchow,  following  the  observation  of  leukocytes  in
neoplastic tissues, hypothesized that chronic inflammation could contribute to
the tumorigenic process. In the following decades, several lines of evidence
suggested  a  strong association between chronic  inflammation and increased
susceptibility  to  neoplastic  transformation  and  development.  It  has  been
estimated  that  up  to  20% of  all  tumors  arise  from conditions  of  persistent
inflammation, such as chronic infections or autoimmune diseases. Indeed, the
association between cervical cancer  and papilloma virus,  gastric  cancer and
Helicobacter  pylori  induced  gastritis,  esophageal  adeno-carcinoma  and
Barrett’s  metaplasia,  hepatocellular  carcinoma,  hepatitis  B  and  C  viral
infections, and many others are well recognized  (Anand P. et al. 2008). The
mediators and cellular effectors of inflammation are important constituents of
the  local  environment  of  tumors.  In  some  types  of  cancer,  inflammatory
conditions are present before a malignant change occurs. Conversely, in other
types  of  cancer,  an  oncogenic  change  induces  an  inflammatory
microenvironment that promotes the development of tumours. Regardless of its
origin,  chronic  inflammation  in  the  tumour  microenvironment  has  many
tumour-promoting effects such as proliferation and survival of malignant cells,
promotes angiogenesis  and metastasis,  subverts  adaptive immune responses,
and  alters  responses  to  hormones  and  chemotherapeutic  agents.  The
inflammatory microenvironment of neoplastic tissues is characterized by the
presence of host leukocytes both in the supporting stroma and among the tumor
cells, with macrophages, dendritic cells, MCs, and T cells being differentially
distributed (Balkwill and Mantovani, 2001). Several cytokines (TNF, IL-1, IL-
6) and chemokines that are produced by the tumor cells and by leukocytes and
platelets associated with the tumor have been found to be able to maintain the
invasive  phenotype  (Coussens  and  Werb,  2002).  Tumor-associated
macrophages  (TAMs)  are  a  major  component  of  the  leukocyte  infiltrate,
initially recruited by inflammatory chemokines (e.g., CCL2) and then sustained
by cytokines present in the tumor microenvironment (e.g., CSFs, VEGF-A). By
producing cytokines such as TGF-β, IL-10, and M-CSF, TAMs promote tumor
proliferation and progression and stroma deposition and, indeed, the density of
TAMs  is  increased  in  advanced  thyroid  cancers  (Ryder  et  al.,  2008).  The
connection between inflammation and cancer can be viewed as consisting of
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two pathways: an extrinsic pathway, driven by inflammatory conditions that
increase cancer  risk (such as inflammatory bowel disease);  and an intrinsic
pathway, driven by genetic alterations that cause inflammation and neoplasia
(such as oncogenes). The intrinsic pathway was uncovered when addressing
why inflammatory cells and mediators are present in the microenvironment of
most, if not all, tumors and therefore are present in cases for which there is no
epidemiological  basis  for  inflammation.  This  finding raised  the  question  of
whether the genetic events that cause neoplasia in these cases are responsible
for generating an inflammatory environment. This question has been addressed
only  recently,  by  using  preclinical  and  clinical  settings  in  which  various
oncogenetic mechanisms can be assessed. The intrinsic pathway is activated by
genetic  events  that  cause  neoplasia.  These  events  include  the  activation  of
various  types  of  oncogene  by  mutation,  chromosomal  rearrangement  or
amplification,  and the inactivation of tumor-suppressor genes. Cells  that are
transformed  in  this  manner  produce  inflammatory  mediators,  thereby
generating an inflammatory microenvironment in tumors for which there is no
underlying inflammatory condition (for example, breast tumors). By contrast,
in the extrinsic pathway, inflammatory or infectious conditions augment the
risk of developing cancer at certain anatomical sites (for example, the colon,
prostate  and pancreas)  (Colotta  et  al.  2009).  Thyroid cancer  obeys to  these
rules.  First,  an inflammatory component,  which includes different leukocyte
types, is frequently observed in thyroid tumors and the papillary histotype of
thyroid  cancer  (PTC)  is  often  associated  with  organ-specific  autoimmune
diseases,  such  as  Hashimoto’s  thyroiditis  and  Grave’s  disease.  Second,
RET/PTC, RAS (V12) or BRAF (V600E), the most common oncogenes found
in human PTC, trigger an inflammatory transcriptional program in thyreocytes
(Melillo RM et al. 2005).
An  inflammatory  component,  which  includes  different  leukocyte  types,  is
frequently observed  in  thyroid  tumors  as  well:  macrophages  and  immature
dendritic cells accumulate in PTCs, both in tumoral stroma and at the invasive
front; the prevalence of lymphocytic infiltrate is generally significantly higher
in patients with PTC than in those with benign thyroid lesions, indicating that
the presence of these cells might favor cancer development; PDCs and ATCs
display  an  increased  density  of  tumor-associated  macrophages  (TAM) with
respect to PTC and FTC; moreover, TAM infiltration positively correlates with
malignant progression of thyroid cancer. MCs (MC) also play an important role
in thyroid neoplastic diseases, because PTCs, but not normal thyroid tissue,
display an intense MC infiltrate whose intensity positively correlates with the
invasive phenotype of TC (Liotti et al. 2012). 
The intrinsic  pathway of  cancer-related inflammation is  driven by the most
frequent genetic alterations associated with thyroid cancer, such as RET and
TRK rearrangements and BRAF and RAS mutations. It has been found that
RET/PTC3 oncogene induces a proinflammatory transcriptional program, that
includes  several  cytokines  such  as  osteopontin  (OPN),  VEGF-A,  CCL2,
CXCL1 and CXCL10. Accordingly, Iwahashi showed that activation of RET
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induces the  production of high levels of IL-8, a pro-inflammatory, mitogenic
and  proangiogenic  chemokine  that  contributes  to  several  human  cancer
(Iwahashi et al. 2002). The proinflammatory properties of RET/PTC in thyroid
might  have  a  dual  effect:  on  one  side,  molecules  such  as  OPN,  CXCL1,
CXCL10, CCL2, GM-CSF can influence immune  response to the tumor by
recruiting and functionally regulating immune cells. On the other side, secreted
cytokines and chemokines, such as OPN, CXCL1, CXCL10, and IL-1 can act
as autocrine growth and survival factors for thyroid tumor cells, which express
the cognate receptors on their plasma membrane (Liotti et al. 2012 ).
1.4 MC and thyroid cancer
MCs (MC) originate in the bone marrow and enter the circulation in immature
form.  Once settled  into  a  tissue  site,  they mature,  taking on characteristics
specific for that tissue.  There are two general types of MC: those found in
connective tissue and those found in mucosal tissue. They have a relevant role
in the pathogenesis of allergic diseases, being stimulated by the IgE-induced
FcεRI receptor activation (Marone et al., 2005). Together with dendritic cells,
MCs  are  among  the  first  immune  cell  populations  to  interact  with
environmental antigens, allergens, bacteria, viruses and parasites (Galli et al.,
2005). The c-kit receptor ligand, Stem Cell Factor (SCF), is the most relevant
factor for human MC maturation and differentiation (Galli et al., 2005). MC
immunological activation results in the secretion of several proinflammatory
factors.  Among the proteins secreted by activated MCs there are preformed
factors (histamine, tryptase, chimase, carbossipeptidase A and proteoglycanes)
stored in secretory granules and extracellularly released within few minutes,
lipidic mediators (cyclooxygenases-PGD2 and PGE2- and the lipo-oxygenase
-LTC4,  LTD4,  LTE4-  metabolites),  several  cytokines  (TNF-  α,  IL-13,  IL-3,
GM-CSF and IL-5) and chemokines (IL-8, CCL3/MIP-1α, CXCL1/GRO-α and
CXCL10/IP-10).  Relevantly,  MCs secretory responses  can be influenced by
both  genetic  and  environmental  factors  (Galli  et  al.,  2005).  MCs,  as
macrophages,  are  long  surviving  cells;  their  number  increases  in  case  of
immediate  hypersensitive  reactions  (rhinitis,  eczema,  asthma),  of  infections
caused by intestinal worms, of chronic inflammation and/or tissue remodeling
(rheumatoid  arthritis,  for  example).  It  is  well  known that  various  types  of
hematologic  malignancies  and  solid  cancers  are  associated  with  increased
MCs. In many tumors, MC counts have been reported to even correlate with
tumor stage, prognosis and invasiveness. ( Ribatti et al. 2011, Pittoni P et al.
2011, Melillo RM et al. 2010, Amini RM et al. 2007, Theoharides et al. 2004).
A correlation between numbers of MCs and poor prognosis was demonstrated
in human lymphoid neoplasms such as Hodgkin´s lymphoma (Molin D et al.
2002),  B-cell  non-Hodgkin’s  lymphoma (Ribatti  D  et  al.  2000),  primary
cutaneous lymphoma (Rabenhorst A et al. 2012) and multiple myeloma (Nico B
et  al.  2008).  Similar  data  were  obtained  in  human  solid  cancers,  such  as
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pancreatic  cancer (Strouch  MJ  et  al.  2010),  hepatocarcinoma,
cholangiocarcinoma (Tereda T et  al.  2000),  prostate  cancer  (Pittoni  P et  al.
2011) and melanoma (Toth-Jakatics R et al. 2000 and Ribatti D et al. 2003). In
a recent  study on human and murine prostate  tumors,  MCs were shown to
increase upon disease. Experiments using MC-deficient mice demonstrated that
MCs  were  necessary  for  development  of  transplanted  well  differentiated
prostate  tumors  progression  (Pittoni  P  et  al.  2011). Similar  results  were
obtained in pancreatic cancer confirming the essential role of MCs for invasion
of tumors (Strouch MJ et al.  2010). Patients with pancreatic cancer showed
elevated serum tryptase levels suggesting that increased numbers of MCs and
MC-conditioned  medium  induced  migration,  proliferation  and  invasion  of
pancreatic  cancer  cell  lines.  On  the  other  hand,  pancreatic  cancer  cells
stimulated migration of MCs (Strouch MJ et al. 2010). In murine pancreatic
cancer, MC numbers were increased and correlated again with tumor grade and
reduced survival (Strouch MJ et al. 2010).  Supernatants of MCs were shown
to induce cytokine release and proliferation of primary cutaneous lymphoma
cells in vitro. Several recent studies also suggested indirect effects of MCs on
tumors  through interaction  with other  immune cells  and blood vessels.  For
example  in  Hodgkin´s  lymphoma,  aggregation  of  eosinophils  together  with
MCs was described to correlate with poor prognosis (Enblad G et al. 1993). In
various tumors including melanoma (Ribatti D et al. 2003), lung cancer (Tomita
M et al. 2000) and squamous cell carcinomas of the esophagus (Elpek GÖ et al.
2001) and cervix (Benitez-Bribiesca L et al. 2001), MC infiltrates correlated to
microvessel  density  in  addition  to  tumor  progression.  In  melanoma,
immunohistological staining showed increased microvessel density correlating
with  MC  numbers  in  lesions  of  poor  prognosis  compared  to  those  of
intermediate  and good prognosis.  Similar  results  were obtained for  primary
cutaneous lymphoma, where increased MC numbers together with increased
degranulation correlated with microvessel density and progression (Rabenhorst
A  et  al.  2012).  Moreover,  several  studies  using  different  tumor  models
observed  reduced  tumor  neo-angiogenesis  associated  with  decreased  tumor
growth in MC-deficient mice (Gounaris E et al. 2007, Rabenhorst A et al. 2012,
Soucek  L et  al.  2007).  Again  supporting  the  concept  of  a  pro-tumorigenic
contribution  of  MCs to  tumors,  several  studies  reported  a  decreased  tumor
growth upon inhibition of MCs. For example, Gournaris et al.  showed, in a
murine colon cancer model, that polyps are infiltrated with MCs and depletion
of  MCs  either  pharmacologically  or  through  generation  of  MC-deficient
chimeric mice lead to profound remission of polyps (Gounaris  et  al.  2007).
Also,  in  tumor  model  of  pancreatic  islet  tumor,  activation  of  Myc  triggers
tumor  expansion  associated  with  recruitment  of  MCs  and  pharmacologic
inhibition of MC degranulation inhibits tumor growth (Soucek L et al. 2007).
MCs were also shown to exert anti-tumorigenic effects in certain malignancies
(Tan SY et al. 2005, Amini RM et al. 2007). Furthermore, patients with low
MC counts showed more pronounced invasion than those with higher numbers
of MCs and, accordingly, the 5-year survival rate was worse in patients with
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low MC counts compared to those with high MC counts. Also, in breast cancer,
stromal MCs were found to correlate with low grade tumors and a favorable
prognosis. Patients with axillary lymph node metastases showed more MCs in
the non-involved axillary lymph nodes, indicating a protective effect of MCs in
breast cancer (Amini RM et al. 2007). The relationship between MC numbers
and tumor invasiveness was recently evaluated in thyroid cancer by our group
(Melillo et al., 2010).
MCs  are  mainly  found  at  the  invasive  front  (the  tumor–host  interface)  of
human tumors, where they may facilitate extracellular matrix breakdown and
tissue remodeling, and thus promote tumor cell motility. In human PTCs MC
infiltrate was present both within the tumors and at the invasive front, but was
virtually absent  from normal tissues;  MC density was increased,  to  various
degrees,  in  95% of a group of PTCs (n=91)  (Fig.  2). Then,  the correlation
between clinicopathological features, angiogenesis and MC infiltrate has been
analyzed. PTCs were divided into two groups: those with intense (+++, ++)
and those with weak (+, -) tryptase staining. The group of PTCs with intense
tryptase staining, tended to be more invasive, as extrathyroidal extension was
more frequent (P=0.0005).
Fig.  2  Immunohistochemical  analysis  of  tryptase  in  human  papillary thyroid  carcinoma  (PTC).  The
degree of tryptase-positive cell staining differed among PTC samples (see samples 2,3,5 and 6). Normal
thyroid tissues (1,4) were negative for tryptase (Melillo et al. 2010). 
Tryptase score                       Clinical features     P value
    Extrathyroidal
    extension   -
    Extrathyroidal
    extension   +
Intense tryptase
staining
    45% (17/38)     77% (46/58)        0.0005
Weak tryptase 
staining
    55% (21/38)    23% (12/58)
Table 1 Correlation between tryptase score and clinical features of PTCs (Melillo et al. 2010).
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In this study, thyroid cancer cells attract MCs through the release of Vascular
Endothelial Growth Factor-A (VEGFA). Moreover, human thyroid carcinoma
cells,  through  the  release  of  soluble  factors,  induce  MC degranulation  and
cytokine  synthesis  in  vitro.  Consistently,  MCs  injected  in  the  tail  vein  of
immunodeficient  mice  are  recruited  to  thyroid  carcinoma  cell  xenografts.
Interestingly,  when  MCs  and  thyroid  cancer  cells  are  co-injected
subcutaneously into nude mice, MCs survive and proliferate, suggesting that
mediators released in situ can induce these effects.  Moreover, when thyroid
cancer  cells  are  treated  with  MC-released  mediators  they  show  higher
proliferation rate, survival capacity and invasive ability. Accordingly, local co-
injection  of  MCs and thyroid  cancer  cells  accelerate  the  growth of  thyroid
carcinoma xenograft  in  athymic  mice.  This  effect  is  mediated by increased
proliferation and vascularization of thyroid cancer cells and reverted by sodium
cromoglycate  (Cromolyn),  a  specific  MC-degranulation inhibitor  (Melillo  et
al.,  2010).  These  data  suggest  that  MCs  exert  a  protumorigenic  effect  on
thyroid cancer.
 
Fig.3 The complex relationship between MC and thyroid cancer cell. MCs exert a protumorigenic effect
in thyroid cancer. They are recruited in tumor site by tumor-derived VEGF-A (and possibly by other
chemoattractants),  and are  activated  by cancer  cell-secreted unknown factors.  Activated MCs secrete
histamine,  and  the  chemokines  CXCL1  and  CXCL10,  that  induce  thyroid  cancer  cell  proliferation,
survival and invasion (Liotti et al. 2012).
These results indicate that MCs are present in PTCs and that their presence and
intensity positively correlate with invasive behavior. The increased motility and
invasiveness  of  tumor  cells  are  reminiscent  of   epithelial-to  mesenchimal
transition (EMT) Thus, it is possible that MCs enhance migratory and invasive
ability of tumor cells through the induction of EMT.
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1.5 Tumor Inflammatory Microenvironment and mediators linking EMT 
and stemness
1.5.1 The Epithelial to Mesenchymal Transition (EMT)
The  Epithelial  to  Mesenchymal  Transition  (EMT)  is  a  conserved
developmental  program whereby a  cascade  of  molecular  and  physiological
changes within a cell results in the transformation of the epithelial cell into a
phenotypically  and  genetically  distinct  mesenchymal  cell.  During  EMT,
epithelial cells lose the adherents junctions that keep them in contact with their
neighbors. They gain a mesenchymal cell phenotype that enables them to break
through  the  basal  membrane  and migrate  over  a  long  distance,  a  result  of
profound changes in their cytoskeleton architecture and gene expression profile
(Kalluri  and  Neilson  2003)  (Fig.  4). However,  this  "transformation"  is
reversible:  mesenchymal  cells  can  revert  back  to  epithelial  cells  through  a
reverse process called mesenchymal-epithelial transition (MET). EMT does not
only occur during embryonic development or as a physiological response to
injury.  It  is  also  an  important  element  in  cancer  progression  and  other
pathologies that involve organ degeneration, such as fibrosis. At the cellular
level, pathological EMTs are very similar to physiological EMTs in that they
are  governed  by  similar  signaling  pathways,  regulators,  and  effective
molecules. From a clinical perspective, metastasis is the most critical aspect of
tumorigenesis (Hanahan and Weinberg 2011). However, additional steps must
be completed before a metastatic tumor is successfully established. The spread
of malignant cells consists of a series of steps, all of which are thought to be
important for metastatic outgrowth in different organs. Basically, these steps
include local invasion toward and entry into blood vasculature (intravasation),
survival  within  the  circulation  system,  arrest  in  distant  capillary  beds  or
“homing” to  distal  organs,  exit  from blood vasculature  (extravasation),  and
eventual outgrowth and re-establishment of malignant growths in secondary
locations (Fidler 2003; Hanahan and Weinberg 2011).
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Fig. 4 In epithelial cells, E-cadherin and integrins provide cell-cell and cell-basement adhesion, respectively (i). During
EMT, the transcription of E-cadherin and integrins in epithelial cells is repressed, inducing the loss of polarity in these
cells (ii). To invade the underlying tissue, the basement membrane is disrupted and the cytoskeleton remodeled to
induce  a migratory morphology (iii).  This  allows  the cells  to detach from the epithelial  sheet  and move into the
surrounding stroma (iv) ( Modified from Acloque et al., 2009).
1.5.2  Characterization of EMTs
EMTs are categorized into three separate types based on the context in which
they occur. Type 1, 2 and 3 EMTs can have different outcomes within a given
cellular context, however it is currently not clear what biochemical elements
they share and how they differ.
Type  1 EMTs  occur  during  development  and  are  utilized  during  discrete
morphogenic  events.  For  example,  the  EMT  program  is  activated  during
gastrulation  in  a  distinct  population  of  epiblast  cells.  Upregulation  of
transcription  factors  such  as  SNAIL1 leads  to  MMP expression  facilitating
breakdown of the underlying basement membrane and ingression through the
primitive streak. These mesendodermal cells then either undergo reversion of
EMT (termed  MET)  and  form  the  ectoderm  or  retain  their  mesenchymal
properties  and  give  rise  to  the  mesodermal  layer.  During  neurulation,
populations  of  migratory  cells  termed  neural  crest  cells  are  formed  at  the
neuroectoderm-ectoderm  junction.  Activation  of  EMT  facilitates  their
delamination  and  subsequent  migration  throughout  the  developing  embryo
where these cells give rise to various tissues.
Type 2 EMTs are associated with inflammation and involve the conversion of
epithelial cells to mesenchymal cells in response to physiologic stress and are
critical  to  tissue  repair  and  regeneration.  The  re-epithelization  stage  during
wound-healing  involves  drastic  changes  in  the  morphology and function of
surrounding  keratinocytes.  During  wound  closure,  keratinocytes  activate  a
partial and reversible EMT to decrease intercellular adhesion and increase their
cell-matrix interaction to migrate over and close a lesion. Type 2 EMT can also
be  activated  in  tissues  undergoing  pathologic  stress.  For  example,  liver  or
kidney damage can lead to the formation of fibroblasts from existing epithelial
cells  to  promote  tissue  repair.  Although type  2  EMTs normally cease  once
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inflammation  has  subsided,  persistent  inflammation  can  lead  to  constitutive
activation of EMT and tissue or organ damage.
Type 3 EMTs are specific to neoplastic epithelial  cells that have undergone
genetic changes including upregulation of oncogenes and decreased expression
of tumor suppressor genes. The activation of EMT in cancer cells can render
them far more invasive and malignant than those cells undergoing type 1 and 2
EMTs. This is possibly due to their ability evade the normal checkpoints and
controls of the body. Increasing evidence suggests that the metastatic spread of
cancer cells is facilitated through activation of EMT in a subset of tumor cells
during cancer progression. The absence of E-cadherin in tumor samples has
long  been  correlated  with  increased  tumor  grade  and  poor  prognosis  and
upregulation  of  numerous  EMT markers  is  also  correlated  with  decreased
patient survival  (Gomez, I  et  al  2011, Kosaka,  T et  al.  2010).  Additionally,
cancer cells at invasive fronts can take on an EMT-like phenotype (Spaderna S
et al. 2006)
1.5.3  Molecular regulation of EMT
The  hallmark  of  EMT is  the  loss  of  E-cadherin  expression,  an  important
caretaker of the epithelial phenotype. Loss of E-cadherin expression is often
correlated with the tumor grade and stage, because it results in disruption of the
cell-cell adhesion and an increase in nuclear beta-catenin (Cowin, Rowlands et
al. 2005; Junghans, Haas et al. 2005). Several transcription factors have been
implicated  in  the  regulation  of  EMT,  including  zinc  finger  proteins  of  the
SNAIL/SLUG family,  the  basic  helix-loop-helix  factors  Twist1/2,  E12/E47,
Goosecoid,  ZEB1and SIP1 (Nieto  2002;  Yang,  Mani  et  al.  2004;  Hartwell,
Muir et al. 2006).
Beside  directly  affecting  gene  expression,  the  zinc  finger  proteins  of  the
SNAIL and  ZEB family  and  the  basic  helix-loop-helix  transcription  factor
Twist1/2  reprogram  gene  expression  by  complex  interaction  with  other
transcription  factors  and pathways  and furthermore  establish  interconnected
feedback  loops  that  sustain  the  morphological  transition.  The  impact  of
SNAIL, SLUG, TWIST and ZEB transcription factors on cell morphology is
based on a common mechanism: all of them have been reported to bind to E-
box motifs of various promoters either transcriptionally repressing or activating
the downstream gene (Peinado et al. 2007; Vesuna et al. 2008; Mironchik et al.
2005).  EMT transcription  factors  have  been  shown  to  equip  the  cell  with
migratory  capacity  by  activating  especially  mesenchymal  genes,  including
those encoding for N-cadherin, the extracellular matrix component Fibronectin
and cytoskeletal proteins such as Vimentin and Smooth Muscle Actin (alpha-
SMA)  (LaGamba,  Nawshad,  and  Hay  2005).  In  contrast,  the  repressive
functions of the major EMT transcription factors are much better characterized.
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In  order  to  abrogate  epithelial  cell  morphology,  which  is  characterized  by
strong cell adhesion allowing the formation of a dense but permeable polarized
layer of cells, EMT transcription factors repress a specific set of cytoskeletal,
junctional and other epithelial genes (Fig 5).
Fig. 5 The EMT regulators transform the cancer cells from epithelial-cell like to mesenchymal-cell like 
with suppression of epithelial markers and expression of mesenchymal markers. The final effects on 
cancer cells are cancer metastasis, drug resistance and with features of cancer stem cells. Modified from  
Jin-Yuan Shih and Pan-Chyr Yang, 2011.
Aberrant  activation  of  the  EMT program can  be  hazardous  to  cellular  and
tissue  homeostasis.  For  this  reason,  the  transition  from  epithelial  to
mesenchymal cell is orchestrated via an intricate and complex set of internal
and  external  signals.  The  TGF-β  proteins  are  well-characterized,  potent
inducers of EMT. After injury, metalloproteinases (MMPs) secreted by stromal
cells surrounding a wound can activate TGF-β stored in the extracellular matrix
and stimulate activation of a temporary and reversible EMT in keratinocytes
allowing their migration into the wound site (Savagner P et al. 2005). TGF-β
signals  can  synergize  with  other  major  EMT signaling  pathways  to  induce
EMT.  The  Notch  signaling  pathway  has  been  shown  to  be  a  downstream
mediator TGF-β induced EMT. In mammary epithelial cells, TGF-β activation
induces  the  expression  of  the  Notch  ligand  Jagged1  (Jag1)  and  EMT
progression.  siRNA against  Jag1  inhibits  EMT  despite  TGF-β  expression
(Zavadil J et al 2004). The Wnt pathway is also involved in EMT activation.
Neural crest induction in the chick requires Wnt1-mediated activation of SLUG
(SNAIL2) and  expression  of  a  dominant-negative  Wnt1  inhibits  SLUG
transcription and neural crest  migration.  Twist1 is  also induced by Wnt1 in
mammary ephitelial cells and its promoter is responsive to β-catenin (Howe
L.R. 2003). Although there are limited studies connecting Hedgehog signaling
and EMT, its pharmacologic inhibition in the E3LZ10.7 pancreatic cancer cell
lines restores expression of E-cadherin and decreases SNAIL  expression and
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metastatic  potential  (Feldmann  G  et  al.  2007).  Additionally,  the  Hedgehog
effector Gli can induce SNAIL1 mRNA in RK3E rat kidney cells and results in
nuclear translocation of β-catenin and cell transformation (Li X et al. 2006).
The Src family of tyrosine kinases are found at the inner layer of the plasma
membrane of cells and localize with adherens junctions as well as cell matrix
integrin; elevated Src activity at cell-cell junctions leads to phosphorylation of
E-cadherin  and  β-catenin,  E-cadherin  endocytosis,  adherens  junction
disassembly  and  EMT.  Src  effects  on  cell-cell  junction  is  observed  during
would healing where Src is  activated to promote cell  migration and wound
closure. Receptor tyrosine kinases (RTKs) are a major group of cell-surface
receptors and many of their ligands are inducers of EMT. Epidermal Growth
Factor (EGF) secreted by stromal macrophages can promote EMTs in adjacent
tumor cells. These cells, in turn, respond to macrophage-derived EGF signaling
by secreting  CSF-1,  a  macrophage attractant  and stimulant  (Weinberg  R.A.
2007) thereby perpetuating EMT activation. Hepatocyte growth factor (HGF)
expression in epithelial cells induces SNAIL1 expression and cell scattering
(Grotegut R et al. 2006). Platelet-derived growth factor (PDGF) overexpression
in  prostate  cancer  cells  leads  to  E-cadherin  downregulation  via  mTOR  .
Fibroblast growth factor (FGF) and IGF (Insulin-like growth factor) (Morali
OG et al. 2001, Billottet et al. 2004 )growth factors have also been implicated
in mediating EMT. Ras is a major effector of RTK-mediated EMT (Edme E et
al. 2002) and acts through the MAPK pathway to activate EMT transcription
factors such as SNAIL1, SLUG and Twist1 (Wang Z et al. 2007).
1.5.4 EMT and STEMNESS
A large body of research has described stem cells in normal tissues, which are
capable  of  renewing  themselves  through  asymmetrical  cell  division  while
simultaneously generating committed progenitor cells whose descendants may
eventually differentiate  and carry out  tissue  specific  functions  (Reya  et  al.,
2001).  Recent  evidences  support  the  hypothesis  that  tumors  contain  a
subpopulation of tumor cells called cancer stem cells (CSCs), which exhibit
stem-like cell properties such as the ability to self-renew, form tumor spheres
in low adherence conditions, differentiate into various populations of cancer
cells,  and form new tumors in a xenotransplant system (Dontu et al.,  2003;
Gupta et al., 2009). While some studies suggest that CSC may arise from the
transformation of their normal counterparts, recent observations suggest that
they  originate  from  fully  differentiated  cells  through  an  adaptive
transdifferentiation program (Fig. 6). 
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Fig.  6  The “cancer stem-cell  theory”  is based on the assumption that during tissue regeneration,  the
amplification of progenitor cells opens a window of time suitable for accumulating genetic alterations,
leading to the emergence of cancer  cell-stems (CSCs).  CSCs would thus initiate  and sustain tumour
growth.  Alternatively,  under stress conditions,  fully differentiated cells reacquire stem-like properties,
including self-renewal properties. This gain of function is influenced by microenvironmental conditions.
These cells could potentially be prone to transformation and give rise to CSCs.
CSCs  were  first  identified  in  the  hematopoietic  system (Bonnet  and  Dick,
1997); more recently, however, they have also been discovered in solid tumors,
including those arising in the breast, colon, brain, glioma, melanoma, prostate,
lung, ovarian, renal cell and thyroid carcinomas (Al-Hajj et al., 2003; O’Brien
et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004, Todaro M et al. 2010).
During  the  process  of  tumor  metastasis,  which  is  often  enabled  by  EMTs
(Thiery et  al.  2003),  disseminated cancer  cells  would  seem to require  self-
renewal capability, similar to that exhibited by stem cells, in order to spawn
macroscopic  metastases.  This  raises  the  possibility  that  the  EMT process,
which  enables  cancer  cell  dissemination,  may  also  impart  a  self-renewal
capability to disseminating cancer cells.  Indeed, the metastatic process is  at
least superficially similar to the processes that occur during tissue repair and
regeneration and enable adult stem cells to exit tissue reservoirs (such as the
bone marrow),  enter and survive in the circulation,  and exit  into secondary
tissue  sites,  where  they  proliferate,  differentiate,  and  participate  in  tissue
reconstruction (Kondo et al., 2003).
Together, these diverse lines of evidence suggested a link between cancer stem
cells and the mesenchymal-appearing cells generated by EMTs (Fig.7) (Polyak
and Weinberg 2009)
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Fig.  7 Cancer stem cells may be result  of the induction of EMT in more differentiated cancer cells .
(Modified from http://www.bergenbio.com/science_of_emt)
The  CSC is  thought  to  share  several  key features  with  normal  stem cells:
unlimited  capacity  for  self  renewal,  including  maintenance  of  the  CSC
population through asymmetric division, the ability to differentiate into several
cell lineages and intrinsic resistance against cytotoxic therapies through drug-
efflux mechanisms and slow cell cycling. The identification and analysis  of
CSCs are fundamental for cancer study. The “gold standard” to identify CSCs
is to isolate cells using biomarkers (cell surface marker), to test their sphere-
forming  ability  in  low-adherence  condition  and  tumorigenicity  at  serial
passaging, that is, CSCs derived from primary xenograft tumors should initiate
tumor growth and give rise to secondary tumors. Regarding biomarkers, recent
studies have reported several CSC markers in solid tumors (e.g. CD44+/CD24-
for breast cancer, CD133+ for brain tumor and colon cancer, CD44+ for gastric
cancer).  In  some  types  of  cancers,  two  or  more  different  markers  have
independently  been  identified  in  the  same  type  of  cancer:  for  example,
CD44+/CD24-, aldehyde dehydrogenase 1 (ALDH)  activity, and CD133 for
breast  CSCs;  CD133  and  CD44+/CD24+  for  colon  CSCs.  However,  their
association and/or combination have not been fully investigated.
There are several canonical markers that CSCs shared with normal stem cell:
SOX2 (SRY-related HMG-box gene 2), initially reported to be linked strongly
with the inhibition of neuronal differentiation, has been shown to acts as an
important  transcriptional  factor  to  maintain  the  self-renewal  capability  of
embryonic stem cell (ESCs). OCT4 (OCT3/4), a member of the family of POU
domain transcription factor  known to bind SOX2, is  also the key regulator
essential  for  the  pluripotency  and  self-renewal  of  of  ESCs.  Nanog,  a
homeodomain-containing protein,  maintains pluripotency of mouse ESCs by
inhibiting NFκB and cooperating with Stat3. ABCG2 is a member of the ATP
binding  cassette  (ABC)  transporters,  which  can  pump  a  wide  variety  of
endogenous and exogenous compounds out of cells. Widely expressed in stem
cells,  ABCG2 is  also found to confer the side population phenotype and is
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recognized  as  a  universal  marker  of  stem cells;  Nestin  is  an  intermediate
filament protein that is known as a neural stem/progenitor cell marker. 
Increased aldehyde dehydrogenase (ALDH) is a hallmark of cancer stem cells
measurable  by  the  aldefluor  assay.  Cytosolic  aldehyde  dehydrogenases
(ALDHs)  are  a  group of  enzymes  involved in  oxidizing  a  wide  variety of
intracellular aldehydes into their corresponding carboxylic acids. ALDH1, one
of  19  ALDH isoforms  expressed  in humans, was  a  marker  of  normal  and
malignant human mammary stem cells and a predictor of poor clinical outcome
of breast cancer patients. High ALDH1 activity has been used to define stem
cell  populations in many cancer types has been described in primitive cells
from multiple myeloma, acute myeloid leukemia, pancreatic, breast, and lung
carcinomas (Lohberger et al. 2012).
Recent progress in thyroid cancer biology has revealed that the histological
appearance  and  biological  behaviors  of  thyroid  carcinoma  often  show
heterogeneity,  with  cells  exhibiting  distinct  proliferative  and  differential
capacities (Pilotti  S et  al.  1995, Aratake Y et al.  2006). Emerging evidence
indicates that a rare subpopulation of cells appeared to be cancer stem cells
(CSCs) drive thyroid cancer heterogeneity and contribute to the resistance to
cancer therapy as observed in various cases (Ke CC  et al. 2013, Zheng X et al.
2010, Todaro M et al.  2010). Moreover,  clinical observations have revealed
that CSC marker frequency in thyroid cancer is related to adverse outcomes
(Yun JY et. Al 2013). Thus, CSCs have been indicated to play a crucial role in
the malignant progression and therapeutic resistance of thyroid cancer (Zhu W
et al. 2010). Lan et al and Yasui et al as well as other research groups observed
that more differentiated thyroid cancer cell populations acquire CSC properties
through EMT (Lan L et al.2013, Yasui K et al. 2013). These studies, therefore,
raise the possibility that thyroid CSCs may arise from restricted progenitors or
more differentiated cells that have acquired self-renewing capacity. Compared
with other organs’ cancer, studies of thyroid CSCs are still limited, and further
researches are definitely required, although ALDH is a major marker to enrich
thyroid CSCs (Todaro M et al. 2010, Mika Shimamura et al. 2014).
The CSC hypothesis has fundamental and important clinical implications, as
the current development of cancer therapeutics is largely based on screening
agents with the ability to cause bulk tumor, but not CSC, regression in animal
models or in clinical trials (Bao  et al., 2006; Bao  et al., 2008; Gupta et al.,
2009).   Strategies  aimed  at  efficiently  targeting  CSCs  are  critical  for
monitoring the progress of cancer treatment and for evaluating new therapeutic
agents. The elucidation of signaling pathways which regulate CSC self-renewal
and survival provides potential therapeutic targets. In addition, CSC behaviors
are constantly regulated both by inside regulators such as transcription factors
and external signals from their niches, including neighboring stromal, immune,
and non-stem tumor cells.  Targeting the neighboring non-stem cancer  cells,
stromal cells or the paracrine factors secreted by these cells may target CSCs
indirectly,   thereby contribute  to  long-term remissions  and  treat  carcinoma
resistant to current therapies (Polyak and Hahn, 2006).
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1.5.5 The role of inflammatory cells and cytokines in EMT and stemness
EMT and stemness may be influenced by tumor microenviroment (Joyce and
Pollard 2009), which is composed  by multiple cell types, such as MC (MC),
fibroblasts,  epithelial  cells,  macrophages,  myeloid-derived  suppressor  cells
(MDSCs). Stromal cells are recruited to tumors, not only to enhance growth of
the primary tumor, but also to facilitate its metastatic dissemination to distant
organs (Tse and Kalluri 2007; Lunt, Chaudary et al. 2009). EMT commonly
occurs  at  the  invasive  front  (tumor-stromal  boundary)  of  many  invasive
carcinomas (Christofori 2006; Franci, Takkunen et al. 2006) and is triggered by
cellular signals from microenvironment.  Tumor stroma conteins various cell
types such as cancer associated fibroblasts (CAFs), mesenchymal stem cells
(MSCs) and immune cells (Joyce and Pollard al. 2009, Lin EY et al. 2004, Tse
JC and Kalluri  R 2007, );  CAFs, MSCs and Th2 polarized CD4+/CD8+ T-
lymphocytes  have  been  shown  to  contribute  to  EMT at  the  tumor-stroma
interface  (Santisteban M et al. 2009).  Tumor associated macrophage (TAM),
the major  inflammatory component  of the stroma in malignancies,  promote
proliferation,  tissue  remodelling,  extracellular  matrix,  invasion  and  matrix
breackdown through protease production and release of a variety of growth
factor (Condeelis and Pollard 2006).  TAM have likewise been shown to induce
EMT at  the invasive front  mainly through TNF-α mediated stabilization  of
SNAIL, a key mediator and marker of EMT (Bates RC et al.  2003). TAMs
induced  EMT in  tumor  cells  located  at  the  invasive  front  correlates  with
metastatic disease in a murine breast cancer model.  Several studies indicate
that, once EMT is initiated, the permanence of tumor cells in a mesenchymal
status post-EMT is dependent on the existence of autocrine cytokine and/or
growth factor loops that were initially responsible for the induction of EMT in
the same cells. Induction of tumor EMT was shown to be enhanced by the
secretion  of  a  subset  of  inflammatory  cytokines,  various  chemokines  and
angiogenic  factors,  which  included  TGF-β.  TGF-β is  a  multifunctional
cytokine regarded as being a tumor suppressor in normal epithelial cells and
during early tumor growth, while acting as a potent tumor-promoting factor in
late-stage tumors  (Zavadil  J  et  al  2005).  In late-stage or  metastatic  tumors,
TGF-β promotes  angiogenesis,  recruits  various  cell  types  to  the  site  of  the
tumor,  including fibroblasts  and immune cells,  suppresses a functional anti-
tumor immune response and induces tumor cell migration, invasion and EMT
(Zavadil  J  et  al  2005).  In  multiple  tumor  cell  models,  it  has  also  been
demonstrated that, once tumor cells have undergone EMT, secretion of TGF-β
is markedly upregulated (Kudo-Saito C et al 2009). Once secreted, TGF-β has
the ability to function in an autocrine fashion, contributing to the maintenance
of the mesenchymal and stem cell phenotypes of carcinomas that have passed
through EMT.
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Similar results were observed with the secretion of the cytokine IL-6 (Sullivan
NJ et  al  2009)  or  VEGF (Gonzalez-Moreno O et  al.  2009)  by tumor  cells
undergoing EMT. IL-6 is a pleiotropic cytokine involved in the differentiation
and growth of hematopoietic stem cells,  T cells and B cells, as well  as the
differentiation  of  other  cell  types  that  express  IL-6R  (CD126)  and  the
coreceptor  gp130  (CD130).  IL-6  is  a  well-known  regulator  of  immune
responses and it has also been implicated as a potent growth factor for certain
tumor cell types, including breast cancer cells. Recent reports also demonstrate
a role for IL-6 in tumor EMT and in the acquisition of stemness. Breast cancer
cells overexpressing Twist, for example, have been shown to upregulate the
secretion  of  IL-6  and,  at  the  same time,  to  activate  STAT3,  indicating  the
existence  of  a  positive  feedback  loop  involving  autocrine-mediated  IL-6
signaling events (Sullivan NJ et al. 2009).
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2. AIM OF THE STUDY
MCs (MC) play an important role in the innate and adaptive immune responses
but, recently, their involvement in tumor growth, angiogenesis and metastasis
has been described. Previous data indicate that MC are mainly found at the
invasive front (the tumor-host interface) of human PTCs and the intensity of
such infiltrate correlates with capsule invasion, suggesting a role for these cells
in tissue invasion. 
With this study, we propose:
•  to  identify  the  major  actor(s)  among  MC-derived  mediators  that  could
recapitulate EMT induction, in order to employ a direct-target strategy for the
treatment of thyroid cancer;
•  to  evaluate  whether  MC-induced  EMT  occurs  together  with  increased
stemness of thyroid cancer cells;
•  to  evaluate  whether  the density of MC infiltrate correlates with increased
EMT and stemness in thyroid cancer surgical samples.
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3.MATERIALS AND METHODS
3.1 Cell cultures, transfection and Sphere Forming assay 
Nthy-ori ( or Nthy-ori 3.1) are human SV-40 immortalized thyroid epithelial
cells. Human thyroid  papillary cancer  cell  lines  TPC1 harbor  a  RET/PTC1
rearrangement; the anaplastic cells 8505-C harbor a BRAF (V600E) mutation
in homozygosis (Salvatore et al. 2006). All these cell lines were maintained in
DMEM (Dulbecco’s Modified Eagle Medium), which contains 4.5g/L of LD-
glucose and 0.11g/L of sodium pyruvate, supplemented with 10% fetal bovine
serum, 1% penicillin-streptomycin and 1% glutamine (Life Technologies Inc.,
Pasley,  PA); they were kept  in  incubator  at  37˚C in humidified atmosphere
containing 95% air and 5% CO2. HMC-1 (Human MC Line 1) were kindly
donated  by  JH  Butterfield  and  grown  in  Iscove’s  (Life  Technologies)
supplemented with 10% fetal calf serum without α- thioglycerol (Butterfield et
al., 1988). LAD-2 cells (kindly donated by AS Kirshenbaum) were grown in
StemPro-34 (Life Technologies) supplemented with human recombinant Stem
Cell Factor (100 ng/ml) (Peprotech, Rocky Hill, NY).
For isolation of human lung MCs (HLMCs), lung tissue was obtained from
patients undergoing thoracotomy and lung resection. Macroscopically normal
parenchyma was dissected free from pleura,  bronchi,  and blood vessels  and
minced into a single-cell suspension as previously described (de Paulis et al.
2000). Yields with this technique ranged between 3 x 106  and 18 x 106  MCs,
and  purities  were  between  1  and  8%.  Lung  MCs  were  purified  by
countercurrent elutriation (J2/21; Beckman) and then by discontinuous Percoll
density  gradient  as  previously  described  (de  Paui  et  al.  2000).  MCs  were
further purified to near homogeneity by positive selection using an antibody
anti-CD117  conjugated  to  magnetic  beads  and  retaining  labeled  cells  on  a
selection  column  (MACS  system;  Miltenyi  Biotec,  Bergisch  Gladbach,
Germany). The final preparations contained > 95% viable cells, assessed by the
Trypan blue exclusion method, and purity was > 98% MCs. 
For the spheroid-forming assay, single cells were plated at 15 cells/ well on
ultra-low-attachment  96-well  or   1500  cells  in  100mm plates  (Corning)  in
serum-free Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 Ham
(DMEM/F12  =  1:1,  Life  Technologies),  supplemented  with  2%  B27  and
enriched for 10 ng/ml of EGF (epidermal growth factor) (Miltenyi Biotec) and
20 ng/ml of bFGF (basic fibroblast growth factor) (Miltenyi Biotec) growth
factors.  Cells  were maintained in a humidified atmosphere of 5% CO2  and
95% air  at  37°C.  Spheres  were  counted  after  15  days.  For  in  vitro  serial
passaging, thyrospheres were collected by gentle centrifugation at 800 rpm for
5 min and dissociated mechancally. The dissociated cells were passed through
40 mm mesh filters (BD Falcon Cell Strainer, Franklin Lakes, NJ) to eliminate
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doublets or triplets. Single cells were plated at 1500 cells/well on ultra-low-
attachment  six-well  plates  to  generate  secondand  third  generations  of
thyrospheres or 1 cell/well for Limiting Dilution Assay.
3.2 Protein studies
Protein extractions and immunoblotting experiments were performed according
to standard procedures. Briefly, cells were harvested in lysis buffer (50 mM
HEPES, pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA,
1.5 mM MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4,
10 μg of aprotinin/ml, 10 μg of leupeptin/ml) and clarified by centrifugation at
10,000 x g for 30 min. Protein concentration was estimated with a modified
Bradford  assay  (Bio-Rad,  Munich,  Germany).  Immune  complexes  were
detected with the enhanced chemiluminescence kit (ECL, Amersham).
3.3 Generation of stable clones
850-5C cells  at  approximately 70% confluence were stably transfected with
pBabe-puro empty vector or co-transfected with pBabe-puro and pCMV6-XL5
IL-8 vector (OriGene) by electoporation method (Neon® Transfection System
for Electroporation, life technologies).  Stably transfected cells were selected
adding puromycin (500 ng/ml) to culture dishes two days after transfection.
Puromycin-resistant  colonies  were  then  harvested  and  analyzed  for  protein
expression and biological activity. 
TPC-1 were tranfected with SLUG Plasmid (#31698-Addgene) or with empty
vector  by  electoporation  method  (Neon®  Transfection  System  for
Electroporation,  life  technologies).  Stably  transfected  cells  were  selected
adding G418 (Life technologies) (1.2 mg/ml) to culture dishes two days after
transfection.  G418 -resistant  colonies  were then harvested and analyzed for
protein expression and biological activity. 
3.4 Antibodies, cytokines and drugs
Anti-ZEB-1,  anti-SLUG,  anti-SNAIL,  anti-phospho-AKT  (specific  for  the
active AKT phosphorylated at Serine 473), anti-phospho-MEK1/2 (specific for
the  active  MEK1/2  phosphorylated  at  Serine  217/221)  and  anti-phospho-
STAT3 (specific  for  the  active  STAT3 phosphorylated  at  Tyrosine  705)  for
Western Blot analysis were from Cell Signaling Technology (Beverly,  MA).
Monoclonal anti-tubulin was from Sigma Chemical Co. Secondary anti-mouse
and anti-rabbit (Biorad) antibodies are coupled to horseradish peroxidase. Anti-
Claudin-1 for Immunofluorescence analysis  and for Facs analysis  was from
Acris Antibodies (Germany), PanCytokeratin Ab from Sigma Aldrich. Human
CXCL8/IL-8 Mab (Clone 6217), Human CXCR1/IL-8 RA Mab (Clone 42705),
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Human CXCR2/IL8 RB (Clone 48311) were from R&D; HA-probe (Y-11) SC-
805 from Santa Cruz.  ɑ-IL6, ɑ-IL8 and ɑ-TNFα for immunodepletion were
from BD Biosciences. Recombinant human TGF-β, IL-6, IL-8 and TNFα were
from Peprotech. S31-201-STA3 inhinitor-(Selleck), LY-294002-AKT inhibitor-
(Cell  Signaling  Technology),  U0126-MAPK  inhibitor-(Cell  Signaling
Technology) and Cromolyn sodium salt -Mast cel inhibitor-(Sigma-Aldrich).
3.5 RNA, cDNA and Q-PCR
Total RNA was isolated by the RNeasy Kit  (Qiagen Hilden, Germany); the
principle of this purification is the affinity chromatography during which RNA
longer  than  200  bases  binds  to  the  RNeasy  silica  membrane.  Cells  were
harvested in lysis buffer RTL supplemented with β-mercaptoethanol (10 μl per
1 ml of lysis buffer). After the addition of ethanol 70%, the lysate was loaded
on the column and centrifuged. Then, the washing buffer RW1 was added into
the column which was centrifuged again and, consequently, it has been possible
to carry out the treatment with DNase, dissolved in buffer RDD, to eliminate
possible  contaminations  due  to  the  presence  of  total  genomic  DNA.  Other
washes  were  performed  with  RW1  and  RPE  buffers;  RNA,  bound  to  the
affinity column’s resin, was eluted by adding sterile H2O RNase free (DEPC
water), to avoid degradation. It is possible to proceed with the cDNA synthesis.
Random-primed first strand cDNA were synthesized in a 50 μl reaction volume
starting from 2  μg RNA using the GeneAmp RNA PCR Core Kit (Applied
Biosystems,  Warrington,  UK).  RNA was  incubated  with MgCl2,  10x buffer
solution,  Random  Hexamers  (RH),  RNase  Inhibitor  (RI),  dNTP
(Deoxyribonucleotide triphosphate) and Reverse Transcriptase (RT). To start
the cDNA synthesis, the enzyme uses an RNA-complementary oligonucleotide;
the synthesized single-strand DNA is then used as template for the synthesis of
the second strand and then for the amplification with PCR. RNase (usually
derived from the bacterium Escherichia coli) degrades the original RNA strand
that has been used as a template by reverse transcriptase. Thus, the mechanism
consists  of repeated cycles of amplification:  denaturation of DNA template,
primers-annealing  to  the  target  sequence  (which  occurs  at  the  annealing
temperature  dependent  on  their  length  and  base-composition)  and  a  final
extension.
Q-PCR allows  to  measure  the  levels  of  a  gene  expression  after  its  cDNA
amplification; a specific fluorescent dye, SYBR Green, which intercalates in
the double-strand DNA, is used to quantize amplified cDNA and the increase
in  fluorescence  is  directly  proportional  to  the  amount  of  amplified  sample
present in the reaction. This method was performed by using the SYBR Green
PCR Master  mix  (Applied  Biosystems)  in  the  iCycler  apparatus  (Bio-Rad,
Munich,  Germany).  Amplification  reactions  (25  μl  final  reaction  volume)
contained 200 nM of each primer, 3 mM MgCl2,  300 μM dNTPs, 1x SYBR
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Green  PCR  buffer,  0.1U/  μl  AmpliTaq  Gold  DNA Polymerase  (Applied
Biosystems),  0.01U/ μl Amp Erase (Applied Biosystems),  RNase-free water
and 2 μl cDNA samples. Thermal cycling conditions were optimized for each
primers  pair.  To  verify  the  absence  of  non-specific  products,  80  cycles  of
melting  curve  (55°C for  10  sec)  were  performed.  As  previously described,
amplification is monitored by measuring the increase in fluoresce caused by
the  SYBR-Green  binding  to  double-strand  DNA and  the  amplification  of
GAPDH  (Glyceraldehyde  3-phosphate  dehydrogenase:  housekeeping  gene,
constitutively  expressed)  was  used  for  normalization.  Fluorescent  threshold
values were measured in triplicate and fold changes were calculated by the
formula  2-(sample  1  ΔCt  -  sample  2  ΔCt),  where  ΔCt is  the  difference  between  the
amplification fluorescent thresholds of the mRNA of interest and the GAPDH
mRNA.  Primers  were  designed  by  using  software  available  at
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi  and  synthesized  by
CEINGE (Naples, Italy).
The employed primer sequences are reported below:
hSOX2            F 5'-gcgaaccatctctgtggtct-3'
                        R 5'-aaaatggaaagttgggatcg-3'
hNANOG       F 5'-tacctcagcctccagcagat-3'
                        R 5'-ttgctattcttcggccagtt-3'
hABCG2        F 5'-tggatttacggctttgcagc-3'
                       R 5'-tcctgttgcattgagtcctgg-3'
hOCT4          F 5'-agcaaaacccggaggagt-3'
                       R 5'-ccacatcggcctgtgtatatc-3'
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hALDH         F 5'-gcaactgaggaggagctctg-3'
                       R 5'-ttcgattaaatcagccaacttgt-3'
hSLUG          F 5’-ccttcctggtcaagaagcat-3’
                       R 5’-cacagtgatggggctgtatg-3’
hGAPDH       F 5’-ctgccactgaaaaggaggag-3’
                       R 5’-ttggcactccttgggttatc-3’
hZEB-1         F  5’-aactgctgggaggatgacac-3’
                      R  5’-gtcctcttcaggtgcctcag-3’
h SNAIL        F  5’-ctctaggccctggctgctac-3’
                       R  5’-gcctggcactggtacttctt-3’
hVimentin     F 5’-gtttcccctaaaccgctagg-3’
                        R 5’-gacacggacctggtggac-3’
h E-Cadherin F 5’-tgcccagaaaatgaaaaagg-3’
                        R 5’-gtgtatgtggcaatgcgttc-3’
hMMP3          F  5’-tgctttgtcctttgatgttg-3’
                        R  5’-ggaagagatggccaaaatga-3’
40
hMMP10       F  5’-gaggaggactccaacaagga-3’
                       R  5’-tccaacccaaggaacttctg-3’
hMMP12      F  5’-cgtggaggtcatggagactt-3’
                      R  5’-ttcgtcctcatcgaaatgtg-3’
3.6 Wound Healing
The Wound Healing assay is a simple and inexpensive method used to estimate
the migration and proliferation rates of different cells and culture conditions in
vitro mimicking cell migration during wound healing in vivo. The basic steps
involve creating a “wound” in a cell monolayer, capturing the images at the
beginning and at regular intervals during cell migration in close the wound and
comparing the pictures with a positive and/or negative control to estimate the
migration rate of the cells. Confluent monolayers of TC cells were treated with
mitomycin (2μg/ml for 2 h) (Sigma-Aldrich, USA). Wounded monolayers were
incubated for 12 or 24 h at  37°C.  Migration was assessed by counting the
number of cells that crossed the wound border.
3.7 Immunofluorescence
Samples  were  fixed  with  100% ethanol  for  30  minutes  at  +4°C  and  with
acetone  for  3  minutes  at  -20°C  and  then  washed  twice  with  PBS1x.
Subsequently, cells were incubated in 1% BSA-PBS1x solution for 20 minutes
at RT (Room Temperature) to saturate non-specific binding sites and washed
three  times  with  PBS1x.  The  primary  antibodies,  dissolved  at  working
concentration  in  0,2%  BSA-PBS1x  solution,  was  applied  and  cells  were
incubated for 1 hour at 37°C in humidified atmosphere. After three washes,
samples were incubated for 45 minutes at 37°C in humidified atmosphere with
the secondary antibody, and dissolved 1:50 in 0,2% BSA-PBS1x. After three
washes,  cells  were  incubated  for  20  minutes  at  RT  in  dark  humidified
atmosphere with DRAQ5 (a red nuclear dye with high affinity for double –
stranded  DNA,  dissolved  1:1000 in  PBS1x).  Cells  were  also  stained  with
Hoechst (a blue fluorescent dye used to stain DNA and dissolved 1:8000 in
PBS1x)  and  incubated  for  5  minutes  at  RT.  After  the  last  two  washes,
coverslips  were  mounted  with  a  drop  of  Mounting  Medium  (3μl,
glycerol/PBS1x  1:1)  and  cells  were  visualized  using  Zeiss  LSM  (Laser
Scanning Microscope) 510 META confocal microscope.
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3.8 ELISA assay
Thyroid cells plated in 6-well dishes were allowed to grow to 70% confluency
and  then  serum-deprived  for  24  h.  Culture  media  were  cleared  by
centrifugation at 2,000 RPM at 4°C to remove detached cells and debris. IL-8,
TNF-α  and  IL-6  levels  in  culture  supernatants  were  measured  using  a
quantitative immunoassay ELISA kit (QuantiKine colorimetric Sandwich assay
ELISA,  R&D  Systems,  UK),  following  the  manufacturer’s  instructions.
Triplicated samples were analyzed at 490 nM with an ELISA reader (Model
550 microplate reader, Bio-Rad).
3.8 FACS Analysis
Briefly, cells were incubated (30 min at 4°C) with specific or isotype control
Abs.  Cells  were  analyzed  with  a  FACS  Calibur  cytofluorimeter  using
CellQuest software (BD Biosciences, Canada). A total of 104  events for each
sample  were acquired  in  all  cytofluorimetric  analyses.  When necessary,  we
performed a cell membrane permeabilization using the Cytofix/Cytoperm kit
(BD Biosciences, Canada).
The ALDEFLUOR assay (Stemcell Technologies) was performed according to
the manufacturer’s guidelines to identify cells with high ALDH activity. Cells
were  suspended  in  ALDEFLUOR  assay  buffer  (~500,000  cells/ml)  plus
BODIPY aminoacetaldehyde  (BAAA),  a  fluorescent  non-toxic  substrate  for
ALDH which freely diffuses into intact and viable cells, and under the enzyme
activity is converted into a metabolite, BODIPY-aminoacate (BAA), which is
retained inside the cells. Cells were incubated for 45 minutes at 37°C. As a
negative control, to estimate background fluorescence, an aliquot of cells from
each  sample  was  treated  with  50  mmol/L  of  the  ALDH  inhibitor
diethylaminobenzaldehyde  (DEAB).  Supernatants  were  removed  by
centrifugation  and  cell  pellets  were  resuspended  in  ALDEFLUOR  Assay.
Buffer to inhibit active efflux of the reaction product. Intracellular fluorescent
product was measured by flow cytometry and sorting gates were established
using the negative controls
3.9 Xenografts in Mice
Each  group  of  10  mice  (4-week-old  male  CD1a  nu/nu)  was  inoculated
subcutaneously into the right dorsal portion with 850-5C pBabe or 850-5C IL-8
cl19 (1×107 cells/mouse grown in adherence condition or thyrospheres derived
cells  1x106  ).  Tumor  diameters  were  measured  at  regular  intervals  with  a
caliper.  Tumor  volumes  (V)  were  calculated  with  the  formula:  V=A×B2/2
(A=axial  diameter;  B=rotational  diameter).  This  study  was  conducted  in
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accordance  with  Italian  regulations  for  experimentation  on  animals.  For
xenograft histological analysis, Ki-67 antibody was from Biocare Medical, and
CD31 antibody was from R&D Systems (USA). 
3.10 Patients and specimens. 
Series of patients was constituted by  30 cases of papillary thyroid carcinomas
were obtained from the files of Pathology Unit, Istituto Nazionale Tumori of
Naples.  All  cases  of  thyroid  carcinomas  and  normal  thyroid  tissues  were
reviewed  according  to  WHO  classification  criteria,  using  standard  tissue
sections and appropriate immunohistochemical slides. Medical records for all
cases  of   thyroid  carcinomas  were  reviewed  for  clinical  information..  The
following clinical and pathological parameters were evaluated for each tumor
included in the study: patient age at diagnosis; tumor size; histologic subtype;
nuclear  grade;  nodal status  (number of positive lymph nodes);  tumor stage;
tumor recurrence or distant metastasis.
3.11 Tissue microarray building
A thyroid Multi-Tumor Array (TMA) was constructed using 30 tumor tissue
samples, using the most representative areas from each single case. All tumors
and controls were reviewed by  an experienced pathologist (R.F.).
Two tissue cylinders from each case with a diameter of 0.6 mm were punched
from morphologically representative tissue areas of each ‘donor’ tissue block
and  brought  into  one  recipient  paraffin  block  (3×2.5  cm)  using  a
semiautomated tissue array (Galileo TMA).
3.12 Immunohistochemistry analysis
Immunohistochemical staining was performed on slides from formalin-fixed,
paraffin  embedded  tissues,  corresponding  to  cases  thyroid  carcinomas  and
normal  thyroid  tissues  to  evaluate  the  expression  of  Tryptse  and  OCT4
markers.  Then, paraffin slides were deparaffinized in xylene and rehydrated
through graded alcohols. Antigen retrieval was performed with slides heated in
buffer EDTA (pH 6 for tryptase and ph8 for OCT4) in a bath for 20 minutes at
97°C. After antigen retrieval, the slides allow to cool. The slides were rinsed
with TBS and the endogenous peroxidase was inactivated with 3% hydrogen
peroxide. After protein block (BSA 5% in PBS 1x), the slides were incubated
with  primary  antibody  to  anti-human  Tryptase  (Dako,  Glostrup,  Denmark
1:100) and Oct4 (Abcam Rabbit Anti-Human Oct4 clone EPR2054 1:500) for 1
hour.  The  sections  were  rinsed  in  TBS  and  incubated  for  20  min  with
Novocastra  Biotinylated  Secondary Antibody (RE7103),  a  biotin-coniugated
secondary  antibody  formulation  that  recognized  goat  and  rabbit
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immunoglobulins. Then the sections were rinsed in TBS and incubated for 20
min  with  Novocastra  Streptavidin-HRP  (RE7104)  and  then  peroxidase
reactivity was visualized using a  3,3’-diaminobenzidine (DAB).  Finally,  the
sections were counterstained with hematoxylin and mounted. For each sample,
at least five fields (inside the tumor and in the area exhibiting tumor invasion,
400 X400) and >500 cells were analyzed. 
3.13 Statistical Analysis
The results are expressed as the mean ± SEM of at least 3 experiments. Values
from groups were compared by using the paired Student  t test or the Duncan
test.  P  value < 0.05 was considered statistically significant.  The association
between  Oct4  and  Tryptase  expression  with  other  clinico-pathological
parameters  was conducted using the χ2. The level of significance was defined
as P<0.05. All the statistical analyses for IHC were carried out using Statistical
Package for Social Science v. 20 software (SPSS Inc., Chicago, IL, USA).
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4. RESULTS
4.1 MC conditioned medium induces EMT in thyroid cancer cell
Recently, we have shown that human thyroid carcinoma cells are a powerful
chemoattractant for mast cells (MC) and this effect requires thyroid carcinoma
(TC)-cell-derived  VEGF-A.  Moreover,  human  TC  cells  induce  MC
degranulation and cytokine synthesis in vitro. MC-released mediators enhanced
proliferation,  survival  and  invasive  behavior  of  TC  cells  in  vitro;  the  co-
injection of MC and TC cells accelerated the growth of TC cell xenograft in
athymic  mice.  Consistently,  the  inhibition  of  MC  function  by  a  specific
inhibitor,  sodium  cromoglycate  (Cromolyn),  blocked  tumor  expansion  by
inhibiting proliferation of cancer cells. Finally, we found that human papillary
thyroid carcinomas (PTCs) feature a remarkable MC infiltrate, whose density
correlates with tumor invasinveness (Melillo et al. 2010); it is possible that the
acquisition of invasive phenotype underlies the induction or enhancement of
the  EMT process. To  investigate  whether   MC have  a  role  in  promoting-
enhancing  EMT,  we  used  different  cell  lines:  human  SV40-immortalized
thyroid  cells  Nthy-ori  (or  called  Nty-ori  3.1),  human  anaplastic  thyroid
carcinoma cells  (ATC) 850-5C; and TPC1, derived from a human papillary
thyroid carcinomas (PTC); MC lines, LAD2 and HMC-1 derived, respectively,
from a human mastocytosis  and from a  human MC leukemia  expressing  a
constitutively active c-Kit mutant (Butterfield et al., 1988) and human primary
MCs derived from human lung (HLMC).
We treated human thyroid normal and cancerous cell lines with  HMC1-derived
conditioned media (MC CM), non-conditioned medium  (DMEM, Dulbecco’s
Modified Eagle Medium), or exogenous TGF-β, a known inductor of EMT,
used as a positive control, for 24h (Fig 9) and evaluated cell morphology. Both
normal and cancer thyroid cells show a classical epithelial morphology when
cultured in their growth medium. By contrast, cells cultured in MC CM or in
the presence of TGF-β showed a striking morphological change. These cells
displayed  loss  of  epithelial  morphology,  became  spread,  and  acquired  a
mesenchymal  phenotype,  reminiscent  of   EMT.  Since  similar  data  were
obtained by using LAD2 and HLMC conditioned medium (not  shown),  we
decided to use HMC-1 CM (MC CM) for all the following experiments, and
named HMC-1 cells MC throughout the thesis.
During EMT, cell–cell adhesion must be lost to produce individual migrating
mesenchymal-like cells. This is mainly achieved through the suppression of E-
cadherin.  Various  transcription  factors  such  as  SNAIL  (SNAIL1),  SLUG
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(SNAIL2), SIP-1, ZEB-1, E12/E47 (Peinado et al., 2004), and Twist1/2 (Yang
et  al.,  2004),  bind  the  promoter  of  the  E-cadherin gene  to  repress  its
transcription. The EMT transcription factors have been shown to repress other
tight junction proteins such as claudins, occludin, and ZO-1 (Ikenouchi et al.,
2003; Ohkubo and Ozawa, 2004). The acquisition of mesenchimal features is
also determined by the expression of mesenchimal markers such as N-cadherin,
fibronectin,  vimentin and  β-catenin.  To verify whether  MC CM can induce
molecular markers of EMT in Nthy-ori,  TPC-1 and 850-5C cell lines,  these
cells were treated with MC CM for 24h, after which they were harvested and
the  expression  of  EMT markers  was  evaluated  by  Quantitative  Real  Time
Polymerase Chain Reaction (Q-PCR).
Fig. 9  Morphological appearance of  Nthy-ori, TPC-1 and 850-5C cell lines after 24h treatment with non-
conditioned  culture  medium  (NT),  HMC-1  Conditioned  Medium  (MC  CM)  or  exogenous  TGF-  β
(50ng/ml). 
Some  EMT markers  were  overexpressed  in  thyroid  cancer  with  respect  to
Nthy-ory cell line in basal conditions and  each cell line displayed a peculiar
pattern  of  gene  expression  (not  shown).  However,  as  shown in  Fig.10,  the
mRNA expression  level  of  several  EMT markers  (Twist1,  SLUG,  SNAIL,
ZEB-1 and Vimentin) increased after MC CM treatment while E-Cadherin, the
46
epithelial  cell  marker,  decreased in treated with respect to untreated thyroid
cells. A significant induction of mRNAs encoding SNAIL in TPC-1 cell line
and Twist1 in 8505-C cell line was observed. Moreover, Nthy-ori cells display
a strong increase of Twist1, SLUG and Vimentin. A decrease in E-Cadherin
mRNA levels was observed in the three cell lines.
Fig. 10 Evaluation of EMT marker mRNA levels by Quantitative Real Time Polymerase Chain Reaction 
in Nthy-ori, TPC-1 and 850-5C cell lines after 24h treatment with MC CM, NT: untreated cells.
Western blot analysis (Fig.11) was used to confirm the induction of selected
EMT proteins. To this aim, we performed a time-course experiment (1h-24h),
and  verified  that  the  protein  levels  of  the  transcriptional  regulators  SLUG,
SNAIL, and ZEB-1 accumulated with different kinetics in the three cell lines.
In particular, SLUG increase preceded ZEB-1 and SNAIL induction in Nthy-
ori cells. In TPC-1 and 850-5C cells, ZEB-1, SLUG and SNAIL progressively
accumulated.  The differences observed in  the kinetics  of induction of EMT
transcription factors may reflect differences in the genetic background or/and
in the malignancy of  in  the  three cell  lines.  Whatever  the case,  the results
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obtained indicate that MC CM is a strong inducer of EMT in thyroid immortal
and malignant cells.
Fig.  11  Protein  expression  of  the  EMT transcription  factors  (SLUG,  SNAIL,  ZEB-1)   analyzed  by
Western Blot analysis in Nthy-ori, 850-5C and TPC-1 cell lines. Anti-tubulin monoclonal antibody was
used as a control for equal loading.
It  is  well  documented that matrix metalloproteases (MMPs) are involved in
EMT through three distinct mechanisms: (a) elevated levels of MMPs in the
tumor microenvironment can directly induce EMT in epithelial cells, (b) cancer
cells that undergo EMT can produce more MMPs, facilitating cell invasion and
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metastasis, and (c) EMT can generate activated stromal-like cells  that drive
cancer  progression  via  further  MMP production  (Evette  S  Radisky  2010).
Matrix  metalloproteinases  (MMPs)  degrade  and  modify  the  extracellular
matrix  (ECM)  as  well  as  cell-ECM  and  cell-cell  contacts,  facilitating
detachment of epithelial cells from the surrounding tissue. They differ from
each  other  in  their  structural  domain  architecture,  substrate  specificity,
temporal and tissue specific expression patterns. MMPs were also named for
their  preferred  substrates  within  the  extracellular  matrix  (ECM):  collagen-
cleaving MMPs (MMP-1, -8, and -13) were designated collagenases, gelatin
(denatured  collagen)-cleaving  MMPs  (MMP-2  and  -9)  were  termed
gelatinases, and MMPs that degraded a broad spectrum of ECM proteins were
called stromelysins (MMP-3, -10,  and -12) or matrilysins (MMP-7).  MMPs
play key functions in embryonic development, but they are also up-regulated in
cancer,  where  they  stimulate  tumorigenesis,  cancer  cell  invasion  and
metastasis.  In  order  to  verify  whether  MC  CM  was  able  to  induce  MMP
expression in our system, we performed a Q-PCR for various MMPs, in basal
conditions and upon treatment with MC CM for 24h, 48h and 72h. As shown in
Fig.12, we found that MC CM treatment caused the upregulation of selected
MMPs in thyroid  cell  lines.  In  fact,  an increased expression  of  MMP12 in
Nthy-ori cell line after 72h treatment with MC CM was observed. Moreover,
TPC-1 cells displayed a strong increase of the mRNA level of MMP3, that
peacked at 48h treatment with MC CM, while in 850-5C cells MMP10 was the
main up-regulated MMP.
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Fig. 12 Quantitative Real Time Polymerase Chain Reaction of Nthy-ori, TPC-1 and 850-5C cell lines
treated or not with MC CM for 24h, 48h and 72h to evaluate the mRNA levels of MMPs (p<0.05).
EMT is also characterized by the acquisition of reduced intercellular adhesion
and  increased  motility  of  epithelial  cells.  These  features  can  be  evaluated
through matrigel migration and wound healing assays. The invasive potential
of  cancer  cells  is  usually  assessed  in  vitro  using  Matrigel  as  a  surrogate
basement  membrane  and  Wound  healing  assay,  that  mimics  cell  migration
during wound healing in vivo. By using Matrigel invasion assays, we showed
that the invasive ability of cancer cell lines treated with MC CM dramatically
increased  compared  with  cells  cultured  in  regular  medium  (not  shown).
Moreover,  we  used  wound healing  assays.  The  basic  steps  of  these  assays
involve creating a "wound" in a cell monolayer, capturing the images at the
beginning and at regular intervals during cell migration to close the wound, and
counting the cell migrated over the wound to quantify the migration rate of the
cells. With these experiments, we showed that the ability of thyroid cells to
close  wounds  in  a  cell  monolayer  was  significantly  increased  by MC CM
treatment, as shown in Fig.13.
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Fig.13  Wound Healing assay on Nthy-ori, 850-5C and TPC1 cell lines treated or not with MC MC for 
12h and growth medium additioned with 10% FBS as a positive control. Representative 
photomicrographs of the wounded cell monolayers are shown. The number of migrated cells over the 
wound in each condition was calculated. (p<0.05) 
MC CM was as effective as complete medium (DMEM 10% FCS) in wound
closure,  indicating  that  MC  CM  contains  soluble  factors  that  can  induce
functional EMT. 
4.2 MC CM treatment causes the loss of tight junctions in TC cell lines. 
Loss of epithelial markers and disruption of the cell-cell junction are hallmarks
of  EMT.  The  tight  junction  (TJ)  is  an  important  structure  that  determines
epithelial cell polarity and disappears during EMT. TJs constitute the epithelial
junctional complex, together with adherens junctions (AJs) and desmosomes,
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located at the most apical part of the complex. TJs create the primary barrier to
the  diffusion  of  solutes  through the  paracellular  pathway and maintain  cell
polarity as a boundary between the apical and basolateral plasma membrane
domains (Schneeberger and Lynch, 1992). The molecular architecture of TJs
consist in three closely related proteins,  ZO-1, ZO-2 and ZO-3, that form the
undercoat structure of TJs together with other peripheral membrane proteins.
The  constituens  of  strand  themselves  are  the  integral  membrane  proteins
Claudins and Occludin; Claudins are 20- to 27-kD integral membrane proteins
with  4  hydrophobic  domains,  2  extracellular  loops  and  N-  and  C-terminal
cytoplasmic domains. The extracellular loops are critical for homophilic and/or
heterophilic interactions with the other TJs proteins and the formation of ion-
selective  channels.  The  intracellular  C-terminal  domain  is  involved  in
anchoring Claudin to the cytoskeleton through interactions ZO-1, ZO-2 and
ZO-3. Currently, 24 claudin genes encoding for the respective proteins have
been identified in human subjects; among them, Claudin-1 is one of the major
structural  and  functional  elements  of  TJs  as  it  plays  a  role  in  paracellular
transport, cellular growth, differentiation and is critical for the manteinance of
cellular polarity. Recent studies show that Claudin-1 is aberrantly expressed in
diverse types of  human cancer and has a causal role in EMT in human cancers
(Junichi Ikenouchi et al. 2003).
To examine whether MC CM affects the expression of epithelial cell markers
and the integrity of on TJs in thyroid cells, we first performed a FACS analysis
for Claudin-1 and Cytokeratin in Nthy-ori and TPC-1 cell lines. As shown in
Fig.14 A, MC CM treatment reduced Claudin-1 an Cytokeratin expression in
TPC-1 and Nthy-ori cell lines. This phenomenon was less evident in 850-5C
cells due to their constitutive low levels of both proteins (not shown).
To confirm this finding and to evaluate the structure of TJs, we performed an
immunofluorescence staining of TPC-1 cell line treated or not with MC CM
with specific anti-Claudin-1 antibodies. As shown in fig.14 B, untreated TPC-1
cells exhibited a regular linear labeling of Claudin-1 at sites of cell-cell contact
regions, indicating that TJs are maintained in this cell line. However, MC CM
caused a dramatic decrease of the protein and a disruption of TJs. 
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Fig. 14 A) FACS Analysis on Nthy-ori and TPC-1 cells treated or not with MC CM for 3h by using
anti.Claudin-1 and anti-pan-Cytokeratin antibody. B) Immunoﬂuorescence microscopy of  TPC-1 cells
with antibody speciﬁc for Claudin-1. In MC CM treated cells Claudin-1 became undetectable in the cell-
cell contact regions. Bars, 10 µm.
4.3 MC CM treatment of human thyroid cancer cells causes the activation 
of AKT and STAT3 pathways
To determine which signaling pathway was involved in MC-mediated EMT
induction,  we  next  treated  thyroid  cells  with MC  CM  and  evaluated  the
activation of various signaling pathways, including MAPK/ERK, JNK, NFkB,
PI3K/AKT  and  STAT3  by  western  blot  analysis  with  antibodies  that
specifically  recognize  activated  isoforms  of  signalling  components  of  the
indicated pathways  (Fig. 15). Among the various pathways tested, we found
that AKT and STAT3 were significantly activated upon MC CM stimulation in
each cell line. In particular, 850-5C cell line displayed a remarkable activation
of AKT that peaked at 1h of MC CM treatment and then decreased. On the
other hand, phospho-STAT3 protein expression levels increased at 1h of MC
CM treatment and accumulated up to 12 hours. In TPC-1 cell line, we found
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that  phospho-STAT3  and  phospho-AKT protein  expression  levels  increased
after 1h of MC CM treatment and persisted for several hours. Finally, in Nthy-
ori we observed the activation of STAT3 that persisted for many hours, while
MEK activation was transient. In both TPC-1 and 850-5C cell lines we did not
appreciate  increase  in  phospho-MEK levels,  probably due  to  the  very high
basal levels displayed by these cells.
Fig. 15 Western Blot analysis of Nthy-ori (A), TPC-1 (B) and 850-5C (C) cell lines treated or not with
MC CM for 1h, 3h, 6h and 12h with anti-phospho-AKT, anti-phospho-MEK and anti-phospho-STAT3
antibodies. Anti-tubulin monoclonal antibody was used as a control for equal loading.
To  assess  whether  AKT  and/or  STAT3  activation  is  necessary  for  EMT
induction/enhancement,  we  evaluated,  by  wound  healing  assay,  MC  CM-
induced  EMT in  TPC-1  in  the  presence  or  in  the  absence  of  U0126,  LY-
294002, or S31-20, inhibitors of MEK, AKT and STAT3 activity, respectively
(Fig.16A).  Sodium  Chromoglycate  (Cromolyn),  an  inhibitor  of  MC
degranulation, was used as a control. As shown in Fig.16 B,  the inhibition of
each  pathway negatively  affected  wound  closure  induced  by MC CM.  We
obtained the same results also in Nthy-ori and 850-5C cell lines (not shown).
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Fig. 16 Wound healing assay performed in TPC-1 cell line treated, for 1h, or not with only MC CM and
with inhibitors S31-201 (100 µM), LY-294002 (50µM), U0126 (20 µM) and Cromolyn (10 µM), as a
control.
4.4 MC-derived factors (IL-6, IL-8 and TNF-α) can induce of EMT in 
human thyroid cell lines. 
MC can produce many different soluble mediators, both in resting conditions
and upon activation. We have previously shown that TC cells can stimulate MC
to degranulate  and produce  soluble  factors   with  protumorigenic  biological
activity (Melillo et al., 2010). Thus, to mimik cancer microenvironment and to
identify MC mediators of EMT, we exposed MC (HMC-1, LAD2 and HLMC)
to TPC-1 and 850-5C cell CM (TC CM). We  defined such cells as “tumor
educated”  MCs  (TEMC).  TEMC  were  evaluated  for  cytokine  production
through RT-PCR and ELISA cytokine arrays. By merging data from the two
different  approaches,  we  consistently  identified  many  cytokines  and
chemokines  produced by MCs whose  levels  could  be  induced  by TC CM,
including  OPN, IL-1β, IL-6, IL-8, TNF-α, CXCL1, and CXCL10 (not shown).
However TGF-β, a know inductor of EMT, was not produced by TEMC. We
also verified whether MC CM  caused an increase in TGF-β levels in TC cells,
by performing an ELISA assay. The data indicated that TGF-β levels did not
change in MC CM-treated with respect to untreated TC cells (data not shown),
indicating that MC CM-induced EMT is not mediated by an induction of  TGF-
β in TC cells.
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Fig.17 Western Blot analysis of Nthy-ori (A), TPC-1 (B) and 850-5C (C) cell lines treated or not with
TNF-α, IL-8 and IL-6 (100ng/ml) at different time points to evaluate ZEB-1, SLUG and SNAIL proteins
expression levels. Anti-tubulin monoclonal antibody was used as a control for equal loading.
Based upon on these data, we supposed that some of the identified cytokines
might be the mediators of  EMT in our system; for this reason, we tested the
capability of  each  cytokine to  induce EMT in our  cells.  The expression  of
biochemical markers of EMT (SNAIL, SLUG, ZEB-1) was evaluated by Q-
PCR (not shown) and western blot analysis on Nthy-ori, TPC-1 and 850-5C
cell lines (FIG.17). We found that, among all the cytokine tested, only TNF-α,
IL-6  and   IL-8  could  induce  EMT.  The  other  mediators  that  we  tested,
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including OPN, CXCL12, IL1β, MIF-1, CXCL1 and CXCL10were either less
powerful  or  uncapable  of  inducing  EMT transcriptional  factors.  To  further
investigate the functional role of IL-6, IL-8 and TNF-α in EMT, we performed
a wound healing assay. Nthy-ori and TPC-1 (Fig. 18) cell lines were treated
with each cytokine or with MC CM, as a positive control. As shown in this
figure, IL-8 induced wound closure similarly to MC CM. IL-6 and TNF-α were
less  efficient  than  IL-8  in  inducing  wound  healing.  We obtained  the  same
results in 850-5C cell line (not shown). 
Fig.18 Wound healing assay on Nthy-ori (A) and TPC-1 (B) cell lines treated with IL-6, IL-8, TNF-α (50
ng/ml) or with MC CM as a positive control. C) The number of migrated cells over the wound in each
condition was calculated (p<0.05).
To confirm the requirement for these factors in MC CM-induced EMT, each
cytokine was inactivated through immunodepletion with specific  antibodies.
Each cytokine was recognized by the specific antibody which,  in turn,  was
bound  to  Protein  G-Sepharose  beads.  The  immune  complexes  were  then
removed from MC CM by centrifugation. Immunodepletion deprived MC CM
form each cytokine, without significantly affecting the levels of the others, as
assessed by ELISA assays (not shown). A representative experiment performed
by using  immunodepleted MC CM on Nthy-ori cells is shown in Fig. 19. After
cells reached confluence, we created wounds in the confluent plates; cells were
then treated with non-conditioned culture medium (NT), complete MC CM or
MC CM immunodepleted of IL-8, IL-6 and TNF-α. We found that the blockade
of IL-8 by neutralizing antibodies inhibited the ability of MC CM to induce
wound repair.
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Fig. 19 A) Wound healing assay with immunodepleted MC CM on Nthy-ori cell line. The removal of each
factor  from MC CM reduced  wound  closure  of  Nthy-ori  cells.  However,  IL-8  depletion  was  more
effective than IL-6 or TNF- removal. B) The number of migrated cells over the wound in each condition
was calculated.   
IL6- and  TNFα-immunodepletion showed less significant  effects.  To further
underline the importance of IL-8,  we observed that  IL-8 add-back to  IL-8-
immunodepleted MC CM restored cell migration. These findings indicate that
IL-8 is necessary to induce EMT in thyroid cells. 
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Fig.20 Fluorescence Activated Cell Sorting (FACS) analysis to estimate cell-surface expression of IL-6R, 
CXCR1 and TNFR in Nthy-ori, TPC-1 and 850-5C cell lines.
Despite IL6 and TNF-α were also present in MC CM and capable of inducing
EMT in Nthy-ori, their ability to induce wound healing was lower than that of
IL-8.  Interestingly, despite TNF-α receptors (TNFR) are expressed on Nthy-
ori,  TPC-1 and 850-5C cell  lines,  IL-6R  is  expressed only in  Nthy-ori,  as
shown in Fig.20. However, all the cell lines expressed high levels of the IL-8
receptors CXCR1 (Fig.20) and CXCR2 (data not shown).
4.5 IL-8 stimulation of TC cells causes an expansion of stem cell 
population.
The  relationship  between  EMT  and  CSCs  has  been  well  documented  in
different types of cancer; EMT inducers or regulators could also induce cancer
cells to acquire stem cell-like characteristics, indicating that there is a crosstalk
between the EMT program and the pathways involved in regulating stemness
(Mani  et al.  2008). Since IL-8 is  the most relevant inducer of EMT in our
system, we asked if IL-8 has any role in the acquisition of stemness features or
in the expansion of stem cell population in TC cells. One of the recognized
features of CSC is their higher aldehyde-dehydrogenase activity with respect to
the other cells.  It  has been demonstrated  that cells  derived from TC tissues
contain a small population of high  aldehyde-dehydrogenase (ALDH) activity.
TC cells with high ALDH expression (ALDHhigh) possessed the ability to self-
renew  and  re-initiate  serial  transplantable  tumors  that  recapitulated  the
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phenotype and metastatic behavior of the parental tumors (Todaro et al. 2010).
In  another  study, (Klonisch  et  al.  2009) ALDHhigh cell  subpopulation  with
potential stem-like characteristics in the ATC cell line 850-5C was identified.
Thus,  we  first  assessed  the  percentage  of  TC  cells  with  high  aldehyde-
dehydrogenase  (ALDH)  activity  by  using  the  Aldefluor  assay, that  uses  a
fluorescent non-toxic substrate for ALDH, which freely diffuses into intact and
viable  cells,  and  under  the  enzyme activity  is  converted  into  a  metabolite,
which is retained inside the cells. The amount of fluorescent reaction product is
proportional to the ALDH activity in the cells and thus to the number of stem
cells. Screening of Nthy-ori, TPC1 and 850-5C cells revealed, in each cell line,
a distinct population with high aldefluor activity (ALDH high
 
 cells) that was
more abundant in the 850-5C, derived from a human ATC; TPC-1 and Nthy-ori
cell lines displayed a low level of ALDH high
 
 cells (Fig.21).
Fig. 21 Percentage of ALDHhigh cells in freshly isolated serum deprived thyroid cells (Nthy-ori, TPC-1
and 850-5C); cells were permeabilized with the Cytofix/Cytoperm Kit (BD). Identification of ALDHhigh
cells was performed using the ALDEFLUOR kit  (StemCell  Technologies).  As a negative control,  an
aliquot of cells from each sample was treated with 50 mmol/L of diethylaminobenzaldehyde, a specific
ALDH inhibitor. Intracellular fluorescent product was measured by flow cytometry and sorting gates.
Another way to isolate cells with stem-like features is to exploit their ability to
growth  in  low  adherence  conditions,  which  favours  the  formation  of  cell
spheroids.  Sphere-forming assays  have  been widely used  to  identify CSCs.
This assay is based on the evaluation of floating non-adherent multicellular
aggregates  obtained  in  suspension  culture  or  cultures  under  non-adhesive
conditions. Cells with stem-like properties are capable to form spheroids under
anchorage-independent conditions in a special serum-free medium enriched for
EGF  (epidermal  growth  factor)  and  bFGF  (basic  fibroblast  growth  factor)
growth factors. In fact, a small number of cells grew out as floating spherical
colonies, which were termed “thyrospheres”, after 7-10 d of culture. During the
next few days, thyrospheres progressively augmented their volume because of
increased cell number. We found that 850-5C, but not TPC-1 or Nthy-ori cells
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formed  spheres  with  high  efficiency  (Fig.  22),  accordingly  with  previous
observations (Shimamura et al. 2014).
Fig.22 A)  Sphere-forming assay.  Quantification of sphere number by the formula (number of formed
spheres/number  of  wells  containing  cells)  x100  in  Nthy-ori,  TPC-1  and  850-5C.  B)  Morphological
appearance of a thyrosphere from 850-5C cells. 
To confirm that thyrospheres were indeed enriched in stem cells, we compared
the levels of stemness markers in 850-5C cells grown in adherence or in low-
adherence conditions. 850-5C thyrospheres displayed higher mRNA levels of
nestin, ABCG2 and ALDH, assessed by QPCR, in comparison to adherent cells
(Fig. 23). 
Fig. 23 Real Time PCR for stem cell markers (Nestin, ABCG2 and ALDH) in 850-5C thyrospheres in
comparison with 850-5C grown in adherence condition (p<0.05).
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To evaluate whether IL-8 receptors were expressed in 850-5C spheroids, we
performed  FACS  analysis  with  anti-CXCR1  and  -CXCR2  antibodies  in
adherent  and  sphere-forming  cells.  This  analysis  showed  that  850-5C
thyrospheres were enriched in CXCR1 and CXCR2 with respect to adherent
cells (Fig. 24).
Fig. 24)  FACS analysis of  adherent 850-5C and 850-5C-derived thyrospheres to evaluate CXCR1 and
CXCR2 expression. 
To assess whether IL-8 could induce/potentiate TC cel stemness, cells were
stimulated with IL-8 and stem cell phenotype was evaluated. IL-8 treatment
significantly  increased  the  percentage  of  ALDHhigh cells  with  respect  to
untreated  Nthy-ori,  TPC-1  and  850-5C  cells.  Moreover,  IL-8  stimulation
caused an increase of stem cell markers (OCT4, SOX2, ABCG2 and NANOG)
with respect to untreated thyroid cells; TGF-β was used as a positive control
(Fig.25 A-B).
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Fig. 25 A) Percentage of ALDHhigh  cells. Thyroid cells (Nthy-ori, TPC-1 and 850-5C untreated, treated
with IL-8 50ng/ml or TGF-β 50ng/ml for 24h were permeabilized with the Cytofix/Cytoperm Kit (BD).
Identification  of  ALDHhigh cells  was  performed  using  the  ALDH kit  (StemCell  Technologies).  As  a
negative  control,  an  aliquot  of  cells  from  each  sample  was  treated  with  50  mmol/L  of
diethylaminobenzaldehyde, a specific ALDH inhibitor. Intracellular fluorescent product was measured by
flow cytometry and sorting gates. B) Q PCR to evaluate the expression levels of stem cell markers in
thyroid cell lines treated or not with TGF-β (50ng/ml), or IL-8 (50ng/ml) for 24h.
As shown in  Fig.26,   IL-8 stimulation induced sphere formation with higher
efficiency  (number  and  dimension,  Fig  26  B-C) in  850-5C  compared  to
unstimulated cells. These spheres were bright, smooth-edged, and compact and
were  clearly  different  from irregular  clumps  of  cells.   Figure  26-A shows
representative photograms reporting the average size of spheres after 15 days
of culture in low-adherent conditions. 
Fig.26 Sphere-forming assay. A) Morphological appearance and average diameters of thyrospheres from
850- 5C cells treated or not with IL-8 (50 ng/ml). B) Quantification of sphere size (mean diameter in μm)
from 850-5C cells treated or not with IL-8 (50 ng/ml). C) Quantification of sphere number by the formula
(number of formed spheres/number of wells containing cells) x100 (p<0.05).
By analysing a panel of  TC cell lines, we found that they all express, to a
different  extent,  detectable  levels  of  IL-8  and  of  its  receptors  CXCR1/2,
suggesting  that  endogenous  IL-8  may  be  important  for  intrinsic  stemness
features of these cells. Accordingly, the ability of each cell line to form spheres,
a typical stemness feature, correlated with endogenous IL-8 levels (data not
shown). In Fig. 27, a representative ELISA assay to evaluate IL-8 levels in the
cell lines used in this study is shown.
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Fig. 27 Elisa assay to evaluate endogenous IL-8 content in Nthy-ori, TPC-1 and 850-5C cell line
Interestingly, we were also able to shown that IL-8 levels were higher in 850-
5C thyrospheres with respect to adherent cells (Fig. 28).
Fig. 28 ELISA assay to quantify the IL-8 content in 850-5C thyrosphere with respect to adherent cells.
Since we have shown that TC cells express endogenous IL-8 and its receptors
CXCR1 and CXCR2, and that these proteins are enriched in thyrospheres, we
aimed at demonstrating that stemness could be inhibited by targeting the IL-
8/CXCR1/CXCR2 axis.  At  this  end,  we blocked this  ligand-receptor  circuit
with neutralizing antibodies anti-IL-8 (2.5 μg/ml), anti-CXCR1(2.5 μg/ml)  or
anti-CXCR2 (1 μg/ml),  and observed a dramatical reduction in sphere-forming
ability of 850-5C cells, as evaluated in terms of sphere number and size. As a
negative control, we used isotype-matched antibody (anti-HA) (Fig.29). These
results  suggest  that  an autocrine IL-8/CXCR1/CXCR2 axis  is  necessary for
thyroid CSCs manteinance.
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Fig.29 The inhibition of IL-8/CXCR1-CXCR2 axis impairs sphere forming ability of thyroid cancer cells.
Anti-IL-8, anti-CXCR1, anti-CXCR2, anti-HA: isotype-matched antibody as negative control. Number
(A) and diameter (B) of formed spheres are decreased when 850-5C cells are treated with anti-IL-8 or
anti-CXCR1 and anti CXCR2. Sphere number (%) was calculated by the formula (number of formed
spheres/number of wells containing cells) x100.  (*= p<0.05; **=p<0.01, ***=p<0.001)
5.6  850-5C engineered to ectopically express IL-8 undergo EMT and 
display stemness features.
In  order  to  obtain  a  stable  EMT  phenotype  in  thyroid  cancer  cells,  we
stimulated TPC-1 cell line, that displayed low basal levels of EMT markers,
with TNFα, IL-6 or IL-8 up to 60 days; we found that IL-8, but not the other
two cytokines (not shown), induced a sustained expression of the EMT markers
SLUG and ZEB-1, but not SNAIL. Moreover,  we evaluated, by QPCR, the
expression levels of stemness markers, and showed that again, IL-8, but not
TNFα or IL-6, could induce sustained expression of various stemness genes.
However,  IL-8  withdrawal  dramatically  decreased  the  levels  of  EMT  and
stemness  markers  (Fig.  30A-B).  These  data  indicate  that  the  continuous
stimulation  with  IL-8  is  required  to  induce  a  stable  EMT phenotype  and
stemness features in TC cells. 
                                      
65
Fig.30 A) Western blot analysis for ZEB-1, SLUG, SNAIL in TPC-1 untreated (NT), treated with IL-8 (50
ng/ml) and upon IL-8 withdrawal (withdrawal IL-8). B) Real Time PCR for stem cell markers performed
in the same conditions as in A). 
In  order  to  obtain  cells  chronically  exposed to  IL-8,  we generated  850-5C
engineered to ectopically express the cytokine (850-5C IL-8); as a control, we
used  empty  vector  transfected  cells  (850-5C pBabe).  IL-8  transfected  cells
were subjected to antibiotic selection and isolated clones were then screened
for IL-8 expression by ELISA assay  (Fig.31A).  Based upon these results,  we
selected 850-5C IL-8 clone 19 and clone 23 for further investigations.
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Fig.31 A) Elisa assay to evaluate the IL-8 content in conditioned media of  850-5C overexpressing IL-8
compared  with  empty  vector-transfected  cells  (pBabe).  B)  Morphological  appearence  of  850-5C
overexpressing IL-8 and relative pBabe clones. C) Real Time PCR  for EMT transcription factors in 850-
5C  IL-8 clones with respect to control clones (pBabe). D) Western blot analysis for EMT markers (ZEB-
1, SLUG, SNAIL and Vimentin) in the same clones; anti-tubulin is used for equal loading. E) Wound
Healing assay in 850-IL-8 clones with respect to pBabe clones: the number of migrated cells over the
wound was calculated. 
850-5C IL-8 cells showed a fibroblast-like morphology, typical of EMT (Fig.
31 B) and displayed overexpression of EMT markers at protein and mRNA
levels with respect to control clones (Fig. 31 C-D); finally, we investigated the
ability of IL-8-transduced cells to migrate in wound healing assays. As shown,
in Fig. 31 E, 850-5C IL-8 clones were able to close the wound more efficiently
than 850-5C pBabe cells. We then studied stemness features of 850-5C IL-8
clones  by  Aldefluor  assay;  the  percentage  of  ALDHhigh cells  was  more
abundant in the two 850-5C IL-8 clones than in control cells, and 850-5C IL-8
clones displayed enriched expression of stem cell markers, compared to control
cells, as tested by Q-PCR analysis (Fig. 32 A, B).
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Fig. 32 A) Cytofluorimetric analysis of ALDH
 high
 cells. 850-5C IL-8 clone 19 and clone 23 displayed
higher ALDH activity than control cells. B) Q-PCR showed elevated levels of stem cell markers in 850-
5C IL-8 cl19 and cl23 with respect to control cells. C) Sphere-forming assay: morphological appearance
and average diameter of thyrospheres from 850-5C IL-8 clone 19 and clone 23. Quantification of sphere
number was obtained by the formula (number of formed spheres/number of wells containing cells) x100.
Quantification of sphere size (mean diameter in  μm). D) Sphere-forming assay under limiting dilution
conditions.  850-5C  IL-8  clones  showed  a  higher  sphere  forming  frequency  than  control  cells.
Quantification of sphere number by the formula (number of formed spheres/number of wells containing
cells) x100. Self-renewal assay. 850-5C IL-8 clones show an increase in sphere number (%) in subsequent
generations;  by  contrast  850-5C  sphere-forming  ability  decreases  at  F3.  Sphere  number  (%)  was
calculated by the formula (number of formed spheres/number of wells containing cells) x100. (p<0.05)
In Fig.32 C, we showed that sphere-forming ability of 850-5C IL-8 clones was
higher  than  that  of  850-5C  pBabe  cells,  in  terms  of  average  number  and
diameter,  providing further evidences of increased stemness features induced
by  IL-8  overexpression.  To  determine  the  number  of  sphere-initiating  cell
contained in a single thyrosphere, we performed a sphere-forming assay under
limiting dilution condition. When single F1 spheres reached the diameter of 70-
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80 μm, they were disaggregated in single cells and plated at the density of a
single cell/well  on ultralow-adhesion 96-well  plates,  using limiting dilution,
verified  microscopically.  Frequency of  formed  thyrospheres  were  estimated
after ~15 days. We found that 850-5C IL-8 clone 19 and clone 23 displayed a
frequency  of  0.9-1.1%  and  1.8-2.0%  sphere-initiating  cells,  respectively,
whereas 850-5C pBabe showed a frequency less than 0.4%. In normal tissues,
stem cell number is constant, because they divide  asymmetrically. By contrast
CSCs possess the ability to expand in number, as occurs during development
or, in the adult,  after tissue injuries, a property that cannot be accounted by
asymmetric  divisions.  Recent  ﬁndings  in  invertebrates  demonstrated  that
increased numbers of SCs can be achieved through rounds of ‘‘symmetric self-
renewing divisions,’’ whereby each SC produces two new cells with identical
SC  fate  and  proliferation  potential  (Morrison  and  Kimble,  2006). Loss-of-
function mutations of cell polarity and cell fate determinants induce CSCs to
divide symmetrically, leading to SC number increase, tissue overgrowth, and,
ultimately,  tumors  (Cicalese  et  al.  2009).  To  determine  the  self-renewal
capacity of sphere-forming cells we performed a self renewal assay (Fig.32 D-
Self renewal assay). 850-5C IL-8 and 850-5C pBabe cells were plated in stem
cell culture medium in 96-well plates at the density of 15 cells per well. This
primary  generation  of  spheres  was  indicated  as  First  generation  (F1).  The
spheres were serially passed through 3 generations, to assess their self-renewal
capacity in vitro. When F1 thyrospheres from 850-5C IL-8 and 850-5C pBabe
grew to 70-80 μm in diameter, spheres were collected and disaggregated, and
then re-plated  in  the  same conditions  (15  cells/well)  in  order  to  form new
spheres and to obtain F2 and, subsequently, F3 thyrospheres. We counted the
formed spheres for three generations and we found that 850-5C IL-8 clones
displayed an increased  sphere number  formation  in  F2 and F3 generations,
whereas 850-5C pBabe decreased thyrosphere-forming ability at F3. As shown
in Fig.33 850-5C IL-8 and pBabe cell-derived thyrospheres displayed a similar
enrichment in CXCR1-CXCR2 levels (Fig.33 A) with respect to adherent cells,
as  assessed  by  FACS  analisys.  However,  IL-8  is  involved  in  maintaining
stemness, as 850-5C IL-8 thyrospheres exhibit higher expression of stemness
markers with respect to those derived from pBabe cells (Fig. 33B). 
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Fig. 33 A) Mean Fluorescence Intensity (MFI)  of CXCR1 and CXCR2 performed  by FACS analysis in
850-5C pBabe and 850-5C IL-8 cl 19 grown in adherence condition with respect thyrospheres (*=p<0.05
CXCR1 and CXCR2 in thyrospheres with respect to pBabe adherent stained for CXCR1 and CXCR2
respectively; §=p<0.05 CXCR2 with respect to IL-8 cl19 adherent stained for CXCR2) . B) We performed
Q-PCR for  stemness  markers  in  850-5C  pBabe  thyrospheres  and  850-5C  IL-8  cl  19   thyrospheres
(p<0.05). 
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4.7 IL-8 increases the tumorigenic potential of 850-5C cells. 
CSCs are believed to be responsible for tumor onset and metastasis. They can
indeed inititiate tumors very efficiently, while the bulk cancer mass, containing
remnant cells, is not able to do so.  As we demonstrated that 850-5C IL-8 cells
contain a higher percentage of CSCs with respect to 850-5C cells, and that 850-
5C IL-8 stem-like cells are endowed with a more efficient ability to proliferate
and self-renew, we decided to verify whether 850-5C IL-8  exhibited a higher
tumorigenic ability in comparison with control cells. To assess tumor growth of
850-5C pBabe and 850-5C IL-8 cl19, we used xenograft injection into athimic
mice.  1x107 cells  from  each  adherent  cell  population  were  injected  sub-
cutaneously into the right dorsal portion of 4-week-old female BALB/c nu/nu
mice (The Jackson Laboratory). Mice were inspected for tumor growth on a
weekly basis. Six weeks later, mice were killed and tumors were excised. 850-
5C IL-8  injected  mice  showed  a  significant  increase  in  tumor  growth  rate
compared to control tumors (Fig. 34 A); no statistically significant differences
were observed in tumor incidence (9/10 850-5C pBabe vs 10/10 850-5C IL-8
cl19). 
To assess the reasons of the increased growth rate of 850-5C IL-8 with respect
to  control  xenografts,  excised  tumors  were  subjected  to  haematoxilin-eosin
(H&E)  staining  and  immunohistochemistry  (IHC)  with  Ki-67,  CD31  and
cleaved caspase3 antibodies. As shown in Fig. 34, the number of Ki-67+ cells
was higher in 850-5C IL-8 than 850-5C pBabe xenografts, indicating that  850-
5C  IL-8  proliferated  faster  than  control  cells  in  xenografts,  although  this
difference  was not  statistically significant  (p  value>0.05). Moreover,  vessel
density, evaluated with anti-CD31 antibodies,  was significantly higher in 850-
5C IL-8 tumors with respect to 850-5C pBabe xenografts (p value˂0.001). No
statistically significant differences were observed in the percentage of cleaved-
caspase 3 stained cells between the two xenograft types (Fig. 34 C).
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Fig. 34 A) Tumor volume of 850-5C pBabe and 850-5C IL-8 xenografts weekly measured (*p<0.05;
**p<0.01). B) A representative picture of tumors excised at the end of the experiment is shown. 
C) Representative 850-5C IL-8 and 850-5C pBabe xenograft sections (magnification 20x),  Hematoxylin
& Eosin analysis, staining  by using different antibodies: Ki-67, CD31, Cleaved Caspase 3. 
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We next compared the tumorigenic potential of 850-5C pBabe and 850-5C IL-8
derived thyrospheres: 850-5C pBabe or 850-5C IL-8 cl19 thyrospheres were
mechanically disaggregated into sigle cell suspensions and injected  (1x106)
into  athimic  mice.  Tumor  incidence  (percentage  of  mice  developing
measurable masses), latency (time to develop measurable masses), and growth
rate were assessed for 7 weeks (Fig. 35). 
Fig.  35 A)  Tumor volume of 850-5C pBabe and 850-5C IL-8 thyrosphere-derived xenografts weekly
measured ( **p<0.01). B) This graph showed the xenografts latency-mean time of thyrospheres derived-
pBabe and IL-8 cl19.
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850-5C IL-8 cl19 thyrospheres were more efficient in  tumor initiation as 10/10
IL-8 cl 19 thyrosphere-injected mice formed tumors while only 6/10 850-5C
pBabe thyrosphere-injected mice did (p=0,04 according to one-sided Fisher’s
exact  test).  Moreover,  850-5C  IL-8  cl19  thyrosphere-derived  xenografts
revealed  a  significantly  higher  growth  rate  with  respect  to  850-5C  pBabe
thyrosphere-derived tumors (p<0.01) as final volume was 0,062 cm3 for 850-
5C pBabe and 0,623 cm3 for IL-8 thyrosphere. 850-5C IL-8 cl19 thyrosphere-
derived xenografts also exhibited a markedly decreased latency-mean time. In
fact,  850-5C IL-8 cl19 thyrosphere-induced tumors appeared between 1 week
(0,002  cm3)  and  14  days  (0,006  cm3)  while  850-5C  pBabe  tumors  only
appeared at 14-21 days from injection (p<0.05) (Fig.35 B). 
4.9 MC density positively correlates with the stemness marker OCT4 in 
human papillary thyroid carcinoma specimens.
As we have shown that MC are a source of IL-8, and IL-8 is an inductor of
EMT and stemness, we asked whether human thyroid carcinomas featuring a
high density of MC also exhibited higher features of EMT and/or stemness. To
this aim, a panel of  30 PTC specimens and 9 normal thyroids were collected,
and a tissue microarray (TMA) was set up and used for IHC. Anti-Tryptase
antibodies,  which  specifically  identify  MC,  and  anti-OCT4 antibodies,  that
detect  a  recognized marker  of  stem cells,  were  used  (Fig.  36).  The age of
patients ranged from 13–61 years, with an average age of 37 years. Tumors
smaller than 2 cm (pT1) were 26,7% (8/30), tumors between 2 and 4 cm (pT2)
were  6,7% (2/10),  tumors  larger  than  4  cm (pT3)  or  with  thyroid  capsule
invasion  were  66,7%  (20/30);  lymph-node  positivity  was  found  in  56,7%
(17/30)  of  patients  at  surgery.  High  OCT4 positivity  was  significantly
associated with T (p-value= 0.010) (Table 2).
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Table  2.  This  Table  summarizes  the  correlation  between  OCT4  expression  and  clinicopathological
parameters in TMA of  human PTC specimens analysed by immunohistochemistry.
Tryptase  expression,  was  low in  12/30 cases  and  high in  18/30.  Statistical
analysis showed that Tryptase expression was significantly associated with T
(p value=0,057) (Table 3). 
PARAMETERS                              TRYPTASE
T Low High P value
T1
T2
T3
5(71,4%)
0
5(26,3%)
2(28,6%)
             2(100%)
14(73,6%)
0,057
LNM
Negative
Positive
4(36,4%)
8(42,1%)
          7(63,4%)
        11(57,9%)
0,76
Capsule Invasion
Negative
Positive
           6(60%)
           6(30%)
           4(40%)
         14(70%)
0,11
Stage
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Parameters                                      
OCT4
T Low High P value
T1
T2
T3
7(100%)
0
15(78,9%)
0
2(100%)
4(21,1%)
0,010
LNM
Negative
Positive
10(90,9%)
14(73,7%)
            1(9,1%)
            5(26,3%)
             0,256
Capsule
Invasion
Negative
Positive
            8(80%)
          16(80%)
           2(20%)
           4(20%)
                1
Stage
T1-T2 N0
Tx N1
         3(100%)
       21(77,77%)
0
6(22,22%)
0,361
 
T1-T2No
TxN1
           2(66,66%)
         10(37,1%)
1(33,33%)
           17(62,9%)
0,320
Table  3.  This  Table  summarizes  the correlation between Tryptase  expression  and  clinicopathological
parameters in TMA of  human PTC specimens analysed by immunohistochemistry.
Moreover,  we  found  a  positive  correlation  between  OCT4  and  Tryptase
expression (p value= 0.025) (Table 4 ).
                                OCT4
TRYPTASE Low High P value
Low
High
       12(100%)
       12(66,66%)  
         0
         6(33,33) 0.025
 
Table 4. In this table we show the correlation between OCT4 and tryptase expression in human PTCs.
Fig. 36  Immunohistochemistry  of human papillary thyroid cancer specimens with anti-OCT4 antibody
and Tryptase staining (brown).
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4.8 SLUG can induce EMT and stemness in PTC (TPC-1) thyroid cancer 
cells.
As SLUG expression was maintained by long-term IL-8 treatment, and 850-5C
IL8 clones  constitutively expressed high  SLUG levels,  we supposed that  it
might be an important mediator of IL-8 biological activity and sufficient to
induce EMT and stem-like features in TC cells. We selected the TPC-1 cell
line,  as  they  featured  very  low  SLUG  expression  and  ALDH  activity,  to
generate  cells  with  ectopical  expression  of  this  transcription  factor.  We
obtained a mass population (mp) and isolated various clones with high SLUG
expression (Fig. 37).  
Fig. 37 A) SLUG protein levels in TPC-1 clones as assessed by western blot. B) SLUG mRNA expression
in TPC-1 SLUG clones by Q-PCR 
SLUG expression in TPC-1 cells enhanced their EMT features. In fact, TPC-1
SLUG cells (cl5) displayed a mesenchimal-like morphology (Fig. 38 A), and
were more efficient in wound closure (Fig.38 B)
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Fig.38 A) Morphological appearance of TPC-1 SLUG cl5 with respect to empty vector cells; B) Wound 
Healing assay shows that SLUG- expressing TPC-1 cells are more efficient in wound closure than 
controls.
Moreover,  TPC-1  SLUG  cells  featured  an  higher  percentage  of  aldefluor
positive cells, upregulation of stemness markers, as shown by Q-PCR assay,
and higher sphere-forming ability with respect to control clones (Fig. 39).
Fig. 39 A) Aldefluor assay to quantify the percentage of aldefluor positive cells in TPC SLUG cl5 with
respect to control cells B) mRNA fold induction of stemness markers in TPC-1 SLUG with respect to
control cells. C) Quantification of sphere number by the formula (number of formed spheres/number of
wells) x100  and of sphere size (mean diameter in μm) (p<0.05).
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Similar data were obtained by enforced expression of  SLUG  in 850-5C cells
(not shown). Interestingly, SNAIL overexpression was not capable of inducing
EMT and stemness in TPC-1 cells (data not shown). Our data indicate that IL-8
stimulates SLUG expression,  and ectopic expression of  SLUG in TC cells
mimics the effects of chronic IL-8 stimulation, suggesting that SLUG might be
a critical mediator of IL-8-induced biological effects. 
To confirm the link between IL-8 and SLUG in thyroid cancer, we performed a
IHC on a panel of 28 human TCs including PTC, FTC and ATC, in order to
evaluate the presence of  IL-8 and SLUG. In accord with previously published
data  (Hardy RG et al. 2007, N Wang et al 2014), we found SLUG expression
in thyroid carcinomas; as shown in Table 5, IL-8 expression correlated with the
presence of lymph-node metastases (LMN) (p = 0.026),  but  not with other
parameters.
IL-8
Histotype Negative Low High P value
Papillary
Follicular
Anaplastic
23(56,09%)
7(87,59%)
1(100%)
9(21,95)
1(12,5%)
0
9(21.95)
0
0
0,436
LNM
Negative
Positive
22(66.11%)
 9(64.28%)
      10(27,77%)
                0
        4(11.11%)
        5(35.71%)
        0,026
Size Negative Low High P value
T1
T2
T3
5(55,55%)
1(25%)
19(67,85%)
2(22,22%)
1(25%)
5(17,85%)
2(22,22%)
2(50%)
4(14,28%)
0,466
Table  5.  This  Table  summarizes  the  correlation  between  IL-8  expression  and  clinicopathological
parameters in a TMA of  human TC specimens analysed by immunohistochemistry.
Moreover, as shown in Table 6 ,  IL-8 expression correlated significantly with
SLUG expression (p value=0,012). 
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                                            IL-8
SLUG Negative Low High P value
Negative
Low
High
17(73,91%)
         6(60%)
         5(38,46)
          6(26,08%)
          0
          4(30,77)
           0
           4(40%)
         4(30,77%)
0,012
Table 6. IHC to shows a positive correlation between IL-8 and SLUG expression in a small series of
human TCs.                                   
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5. DISCUSSION
Thyroid  cancer  (TC)  is  the  most  common  endocrine  malignancy  and  its
incidence is increasing. TC includes well-differentiated (WDTC) follicular and
papillary  (FTC  and  PTC  respectively),  poorly  differentiated  (PDTC)  and
anaplastic  thyroid  carcinoma  (ATC).  Despite  WDTC  has  an  excellent
prognosis,  with  more  than  90%  cured  upon  therapy,  a  small  percentage
(approx.  5%)  of  them become  resistant  to  radioiodine  therapy (radioactive
iodine resistant-RAIR), the main treatment for these patients. RAIR neoplasias
can hardly be cured. RAIR include, beyond WDTC, PDTC, and ATC. 
The recognition that cancer progression is highly influenced by its interaction
with stroma has lead to the concept that cancer management may be improved
by therapeutic  targeting of the tumor microenviroment  (Hofmeister  V et  al.
2008). A full understanding of tumor-strome interaction may allow to identify
novel therapeutical approaches for advanced TC, such as ATC or RAIR, and to
overcome the issue of drug resistance during treatment.
We  have  previously  demonstrated  that MCs  (MC)  are  recruited  in  thyroid
cancer through tumor cell-derived VEGF-A. MC exhibit a pro-tumorigenic role
in thyroid cancer. MC inhibition, by using sodium cromoglycate (Cromolyn),
strongly  reduces  the  growth  of  thyroid  carcinoma  xenografts  in
immunodeficient  mice  (Melillo  et  al.,  2010). Thyroid  cancer  presents  an
intense  MC  infiltrate,  whose  density  correlates  with  invasiveness.  The
increased  motility  and  invasiveness  of  tumor  cells  are  reminiscent  of
Epithelial-to-Mesenchymal  Transition  (EMT),  an  important  step  in  tumor
progression,  responsible  for  the acquisition of  invasive properties  by tumor
cells (Thiery JP 2003). EMT is a well characterized mechanism, through which
epithelial  cells  trans-differentiate  and acquire  an mesenchymal and invasive
phenotype.  Here,  we  demonstrate  that  MC  and  their  mediators  enhance
migratory  and  invasive  ability  of  thyroid  cancer  cells  through  the  EMT
induction. In fact, MC Conditioned Medium (MC CM) treatment of thyroid
cancer  cells  (Nthy-ori,  TPC-1  and  850-5C)  causes  the  acquisition  of  a
fibroblast-like  morphology,  typical  of  the  EMT  program,  induces  the  up-
regulation  of  typical  EMT markers  (SLUG, SNAIL,  ZEB-1,  Vimentin)  and
down-regulation of E-Cadherin (a hallmark of epithelial cells), enhances cell
migration,  as  demonstrated  by scratch  wound  healing  assays.  Moreover,  in
accord with the evidence that EMT causes the loss of the epithelial cell polarity
and the decrease of intercellular adhesion, we found that MC CM treatment of
human thyroid cells causes Tight junction (TJ) destabilization and Claudin-1
down-regulation.  These data,  taken togheter,  indicate  that  MC CM contains
soluble  factors  that  can  induce  or  potentiate  EMT  of  thyroid-transformed
(Nthy-ori) or -cancer-derived (TPC-1 and 850-5C) cells.
We previously showed that  MC,  when co-cultured with thyroid cancer  cell
lines or treated with their  conditioned media (tumor-educated MC, TEMC),
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undergo activation and produce many inflammatory mediators. To identify the
mediator(s) of  MC CM-induced EMT in thyroid cancer cells, we evaluated the
expression of MC mediators in TEMC by qRT-PCR Cytokine Array and by
multicytokine ELISA Array analysis. We found that several MC cytokines and
chemokines are highly up-regulated upon TC treatment. Among the different
mediators, we found that IL-6, IL-8 and  TNF-α are the strongest inducers of
EMT, being IL-8 the most efficient, since it could recapitulate EMT with the
same efficiency of MC CM. In fact, the blockade of IL-8, but not of IL-6 or
TNF-, by neutralizing antibodies inhibits the ability of  MC CM to induce
EMT, as assessed by wound healing, and this effect reverts by an excess of IL-
8. The predominant role of  IL-8 is probably due to higher levels of the IL-8
receptors CXCR1 and CXCR2 in comparison with TNFR and IL-6R.
The initiation and recurrence of  tumors is believed to be strongly linked with
the  biology of cancer stem cell (CSCs). Recent  studies have demonstrated that
EMT plays  a  critical  role  not  only  in  tumor  metastasis  but  also  in  tumor
recurrence and increasing evidences suggest that EMT is also associated with
the generation of CSCs (Dejuan Kong et al. 2011). These cells are well known
to  possess  self-renewal  properties  and  are  retained  responsible  for  tumor
initiation, chemo/radiation therapy resistance, recurrence and metastasis. Thus,
it is important to identify factors that can induce/potentiate CSCs during cancer
progression for the development of novel and targeted therapies for complete
eradication of cancer (Weiyuan Fang et al. 2014).
According with previous observations (Todaro et al., 2010, Shimamura et al.
2014), screening of Nthy-ori, TPC-1 and 850-5C cells revealed, in each cell
line,  a distinct population with high aldefluor activity (a measure of ALDH
activity, that increases in stem cells), that was more abundant in the 850-5C
cells, derived from a human ATC. Consistently, 850-5C, but not Nthy-ori and
TPC-1 cells,  were capable to form spheres when coultured in low-adherence
condition, a well characterized assay to evaluate stemness features.To confirm
that thyrosphere are indeed enriched in stem cells, we compared the levels of
stemness  markers  in  850-5C cells  grown in  adherence or  in  low-adherence
conditions.  850-5C  thyrospheres  display  higher  mRNA  levels  of  nestin,
ABCG2 and ALDH, assessed by quantitative PCR in comparison to adherent
cells. Moreover, FACS analysis showed that the levels of membrane-exposed
CXCR1 and CXCR2 was higher in 850-5C thyrospheres than in adherent cells;
CXCR1high thyrospheres were also positive for SOX2, a recognized stemness
marker  (data  not  shown). Interestingly,  850-5C  thyrospheres  were  also
enriched in IL-8 content with respect to adherent cells. These data indicate that
the subpopulation of TC cells with stemess features is characterized by higher
CXCR1/CXCR2-IL-8 expression with respect to the bulk population. Thus, not
only thyroid cancer cells express the  IL8 receptors CXCR1 and CXCR2, but
also endogenous IL8; despite this, thyroid carcinoma cells are still responsive
to IL8 stimulation. We showed, in fact, that exogenous treatment of  TC cells
with IL-8 causes, besides the induction of the EMT program, the expansion of
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CSC population, as demonstrated by the increased number of  ALDHhigh cells
and  the  expression  of  CSC  markers.  IL-8  stimulation  enhanced  also
thyrosphere-forming ability when TC cells were plated in ultra-low adherent
conditions.  Moreover,  we  show  that  endogenous  IL-8  is  involved  in  the
manteinance of stemness in TC cells. First, endogenous IL-8 levels correlated
with  sphere-forming  ability  in  a  panel  of  TC  cell  lines  (data  not  shown);
accordingly,  when we blocked IL8 signaling  by using neutralizing antibodies
directed to IL-8, CXCR1 or CXCR2, sphere forming capability is significantly
decreased. Thus, the circuit IL8-CXCR1/CXCR2 mediates EMT and stemness
of thyroid cancer cells. 
We tryed to  induce a stable EMT phenotype in TC cell  lines by long-term
stimulation (up to 60 days) with IL-8, that caused an increased expression of
SLUG  and  Zeb1  and  the  acquisition  of  stemness  features.  However,  this
treatment was not able to stably induce these properties, as IL-8 withdrawal
reverted this phenotype. In order to obtain TC cells chronically exposed to IL-
8, we generated 850-5C overexpressing IL-8. These cells underwent EMT, as
shown by mesenchymal-like morphology, increased expression levels of EMT
markers and a higher capacity to repair wounds with respect to parental cells.
IL-8  overexpressing  clones  also displayed  a  higher  stemness  potential  with
respect to control cells. 
Athymic  mice  injected  with  1x107 850-5C  IL-8  adherent  cells  showed  an
increase  in  tumor  growth  in  comparison  to  mice  injected  with  parental  or
empty-vector transfected cells. 850-5C IL-8 exhibited a higher number of ki67
positive cells  than 850-5C xenografts.  However,  this  increase did not reach
statistycal significance. 850-5C IL-8 xenografts displayed instead a significant
increase  in  vascularization  with  respect  to  control  tumors  (p  value<0,001).
Accordingly,  IL-8  overexpressing  cells  did  not  display  a  faster  growth  in
culture. On the other hand, IL-8 is a well recognized proangiogenic chemokine.
Thus, the reason for  the faster  growth rate  of  850-5C IL-8 with respect  to
control xenografts may be due, at least in part, to the augmented vessel density
of the tumors.
We also demonstrated that 850-5C pBabe and 850-5C IL-8 thyrosphere-derived
xenografts feature a higher tumorigenic potential with respect to adherent cells.
In fact, both  850-5C pBabe and  850-5C IL-8  spheroid-derived, were able to
form tumors when injected at  1x106 cells;  however,  850-5C IL-8  spheroid-
derived tumors revealed a significantly shorter latency and a faster growth rate
with  respect  to  850-5C  pBabe  spheroid-derived  tumors  (p  value<0.01).
Moreover, 10/10  850-5C IL-8  spheroid-derived tumors xenografts efficiently
grew in nude mice,  while only 6/10  850-5C pBabe did so,  indicating that
tumor initiation was more efficient in  850-5C IL-8 than in control cells. In
accord with our observations, OCT4 protein expression evaluated in a panel of
30 human PTCs was significantly associated with increased tumor size (T3, p
value= 0.010), and correlated with Tryptase staining, a measure of MC density
(p value=0.025).
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As we demonstrate  that  SLUG expression is  maintained by long-term IL-8
treatment and 850-5C IL8 clones constitutively express high SLUG levels, we
hypothesized it might be an important mediator of IL-8 biological activity and
sufficient  to  induce  EMT  and  stem-like  features  in  TC  cells.  Thus,  we
ectopically expressed SLUG in TPC-1 cell line, that features low basal levels
of this transcription factor. SLUG-overexpressing clones underwent EMT and
acquired increased stemness features with respect to control cells. These results
suggest  that  SLUG may be  a  critical  mediator  of  IL-8-mediated  biological
effects.  However,  to  finally  demonstrate  that  SLUG is  necessary  for  IL-8-
mediated EMT and stemness induction in TC cells, we need to down-regulate
SLUG expression by RNA interference. We generated SLUG-silenced clones
and we are currently characterizing them for EMT and stemness. 
The role of IL-8 in  TC was also confirmed by analysing a limited number
(n=28) of TC surgical samples by IHC for IL-8 and SLUG; we found that IL-8
expression correlates with the presence of lymph-node metastases (LMN)  (p
value=0.026),  but  not  with  other  clinicophatological  parameters,  and  with
SLUG expression (p value =0,012).
It  has been demonstrated that  many types  of  human carcinomas,  including,
breast, colon, cervical, gastric, lung, ovarian and medullary thyroid carcinoma
express high levels of IL-8 relative to normal tissues Palena C et al. 2012 and
Waugh  DJ  et  al  2008).  In  addition,  multiple  clinical  studies  in  MTC,
melanoma,  as  well  as  breast,  ovarian,  prostate  cancer  have  shown a  direct
correlation between serum IL-8 levels and disease progression (Broutin S et al
2011, Xie K. 2001). In recent years, it has also been demonstrated that a link
exists between IL-8 and tumor stemness. The IL-8/CXCR1 axis has been well
documented in breast CSCs. Populations of CSCs, characterized by elevated
activity  of  aldehyde  dehydrogenase,  have  been  shown  to  express  elevated
levels of CXCR1 and, in turn, the addition of purified IL-8 to epithelial breast
cancer cells increased the percentage of aldehyde dehydrogenase-positive cells,
enhance the migration and invasiveness of CSCs in vitro (Charafe-Jauffret E et
al 2009). Blockade of IL-8R activity via neutralizing antibodies or by utilizing
the small-molecule inhibitor of IL-8R, repertaxin,  decreased the breast CSC
population both in vitro and in vivo (Ginestier C, et al. 2010), reinforcing the
importance  of  the  IL-8–IL-8R  axis  in  breast  CSCs.  Additional  studies
conducted with primary colorectal cancer cells transfected with the stem cell-
associated  transcription  factor  OCT4 also  showed that  CSCs secrete  higher
levels of IL-8 and that neutralizing antibodies against IL-8 are able to inhibit
tumorsphere formation along with the expression of the CSC markers CD133,
CD44, SOX2, SNAIL and ABCG2, and decrease resistance to treatment with
5-fluorouracil (Chang CJ.et al 2011). 
Searching for a mediator of IL-8 promoted biological effects, we noted that the
chronic treatment of thyroid cancer cells with IL-8 causes a long term increase
of  SLUG,  an  EMT  regulator  and  a  stem  cell  marker,  that  plays  also  an
important role in promoting tumor progression, invasion, chemoresistance and
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radioresistance to  cancer  therapies  (Shiori  et  al.  2006,  Haslehurst  AM et  al
2012).
In conclusion, this study emphasize the importance of IL-8/CXCR1/CXCR2
axis  in  TC as  an  essential  factor  for  the  induction  and maintenance  of  the
mesenchymal and stem-like phenotype of aggressive, metastatic TC cells; our
data indicate that IL-8 is both produced by stromal cells, such as MC, and
produced  in  an  autocrinous  manner;  therapeutic  strategies  for  aggressive
thyroid  cancer  are  urgently  needed  and  should  target  not  only  the  bulk  of
cancer  cells,  but  also  CSCs,  that  are  probably  responsible  for  tumor
progression and recurrence. Moreover these strategies can also target stromal
cells such as MC. Thus, both endogenous and exogenous IL-8 contribute to
EMT/stemness  of  TC  cells.  We  cannot  exclude  that  other  stromal  cells,
including CAFs and immune cells, may be a source of IL-8. Accordingly, it has
been recently shown that TAM are a major source of IL-8 in PTC. Moreover,
TAMs represent a remarkable portion of stromal cells in ATC (Rayder et al.
2008, Caillou et al. 2011).
Targeting  the  IL-8/CXCR1/CXCR2 could  be  a  promising  startegy to  target
CSCs and to improve the outcome of difficult-to cure forms of TC, such as
RAIR or ATC. 
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6. CONCLUSIONS
Despite  recent  evidences  suggest  the  occurrence  of  EMT and  stemness  in
human  thyroid  carcinomas,  tumor  microenvironment-derived  mediators
capable of provoking these features are unknown. Here, we identify MC as a
critical component of tumoral stroma in TC and we show that IL-8 is the most
important MC-mediator that induces EMT and stemness in thyroid cancer. This
is possibly due to the induction of the EMT master transcription factor SLUG;
accordingly the block of IL-8/CXCR1/CXCR2 axis in  TC cells reverts EMT
and stemness.
Current anticancer treatments are often able to destroy the bulk of a tumor but
spare  CSCs.  Thus,  relapse  or  tumor  recurrence  is  not  rare  after  a  primary
therapeutic  response  or  initial  induction  of  tumor  remission.  An  ideal
therapeutic  strategy  should  not  only  kill  differentiated  cancer  cells  (as
conventional therapy does) but should also specifically destroy thyroid  CSCs
simultaneously.  Thus,  the  focus  on  thyroid  CSCs  has  significant  clinical
implications for the development of novel therapeutical strategies for refractory
thyroid cancer ( such as RAIR and ATC). 
Taken together, our results provide an interesting tool to uncover new avenues
of  therapeutic  intervention  with the  potential  to  go beyond traditional  anti-
cancer approaches:  because their involvement in tumorigenesis, migration and
invasive  ability  through  EMT induction  and  expansion  of  CSC population,
MCs and their mediators are possible therapeutic targets for a novel strategy to
treat thyroid cancer. In particular, we showed that IL-8/CXCR1/CXCR2 axis
has a crucial role, placing neutralizing anti-IL-8 antibodies or small-molecule
inhibitors of CXCR1/CXCR2 at the center of new and interesting therapeutic
investigations.
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